UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 30, 2014

 

VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Yukon Territory, Canada

1-11388

04-3153858

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

150 Commercial Street

Sunnyvale, California

94086

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (408) 530-1900

 

No change

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 1.01     Entry into a Material Definitive Agreement.

 

On September 30, 2014 (the “Closing Date”), Viveve, Inc. (“Viveve”), the wholly-owned subsidiary of Viveve Medical, Inc. (the “Company”), entered into a Loan and Security Agreement and an Intellectual Property Security Agreement with Square 1 Bank (the “Lender”), and the Company executed an Unconditional Guaranty in favor of the Lender and issued to the Lender a warrant (the “Warrant”) for the purchase of the Company’s common stock.

 

Loan and Security Agreement (the “Loan Agreement”) . Pursuant to the Loan Agreement, the Lender provided a term loan to Viveve in the amount of up to $5 million (the “Loan”). The proceeds of the Loan are to be distributed in three tranches. The first tranche of $2.5 million was provided to Viveve on October 1, 2014. The proceeds from the first tranche were used to repay in full the indebtedness owed by Viveve to Oxford Finance LLC in the amount of $1,630,536, and the balance is to be used by Viveve for working capital purposes and general capital expenditures. The second tranche of $1.5 million may be drawn on by Viveve at any time during the period beginning on the date that Viveve provides evidence acceptable to the Lender of at least 50% enrollment in the OUS Clinical Trial and ending on January 31, 2015. The third tranche of $1 million may be drawn on by Viveve at any time during the period beginning on the date that Viveve has provided (i) evidence acceptable to the Lender of positive interim 3-month results from the OUS Clinical Trial and (ii) a favorable call from 5AM Ventures related to an additional investment in Viveve, and ending on June 30, 2015. The proceeds from tranche 2 and tranche 3 are to be used for general working capital purposes and for capital expenditures. Interest accrues at a fixed per annum rate equal to the Basic Rate, as defined in the Loan Agreement, in effect on the date of any tranche 1 advance or tranche 2 advance, respectively, plus the Applicable Margin, as defined in the Loan Agreement, not in any case less than 5.0% per annum. Interest accrues on each tranche 3 advance at a fixed per annum rate equal to the Basic Rate, as defined in the Loan Agreement, in effect on the date of the tranche 3 advance plus the Applicable Margin, as defined in the Loan Agreement, not in any case less than 6.5% per annum. Each advance is due to be repaid 42 months after the date of the advance (the “Term Loan Maturity Date”). Interest only is due and payable monthly during the first 12 months of the loan term (the “Interest Only Period”). The principal balance of each advance that is outstanding at the end of the applicable Interest Only Period must be paid in 30 equal monthly installments of principal, plus all accrued interest, beginning on the first day of the first month following the end of the Interest Only Period, and continuing on the same day of each month thereafter through the Term Loan Maturity Date, at which time all amounts outstanding in connection with any advance shall be immediately due and payable. Advances, once repaid, may not be reborrowed. During the 18 months following the Closing Date, Viveve may prepay the outstanding principal and accrued interest on all (but not less than all) of any advance, together with a prepayment fee equal to 2% of the outstanding balance of the advance. Events of default which may cause repayment of the Loan to be accelerated include (1) non-payment of any obligation when due, (2) the failure to perform any obligation required under the Loan Agreement, (3) the occurrence of a Material Adverse Event, as defined in the Loan Agreement, (4) the attachment or seizure of a material portion of Viveve’s assets if such attachment or seizure is not released, discharged or rescinded within 20 days, (5) if Viveve becomes insolvent or starts an insolvency proceeding or if an insolvency proceeding is brought by a third party against Viveve and such proceeding is not dismissed within 30 days, (6) if Viveve defaults on or fails to perform any agreement (i) resulting in a right by a third party to accelerate indebtedness in an amount in excess of $100,000, (ii) resulting in the termination of the lease of Viveve’s principal place of business or (iii) that would reasonably be expected to have a Material Adverse Effect, as defined in the Loan Agreement, (7) i f a final, uninsured judgment or judgments for the payment of money in an amount, individually or in the aggregate, of at least $100,000 is rendered against Viveve and remains unsatisfied and unstayed for a period of 45 days, or (8) if any material misrepresentation or material misstatement existed in any warranty or representation set forth in the Loan Agreement or in any certificate delivered to the Lender pursuant to the Loan Agreement or to induce the Lender to enter into the Loan Agreement or any other document. The Loan Agreement creates a first priority security interest in favor of the Lender in the Collateral, as defined in the Loan Agreement and set forth in Exhibit B thereto.

 

 

 
 

 

 

Intellectual Property Security Agreement . The Intellectual Property Security Agreement, which is dated as of September 30, 2014, creates a first priority security interest in all of Viveve’s intellectual property. The security interest granted pursuant to the Intellectual Property Security Agreement is in conjunction with the security interest granted to the Lender under the Loan Agreement and the rights and remedies of the Lender with respect to the security interest granted pursuant to the Intellectual Property Security Agreement are in addition to those set forth in the Loan Agreement.

 

Unconditional Guaranty. In consideration for the Loan made to Viveve, the Company agreed to unconditionally and irrevocably guarantee the prompt and complete payment of all amounts owed by Viveve to the Lender pursuant to the Loan Agreement and performance by Viveve of its obligations under the Loan Agreement.

 

Warrant. As additional consideration for the Loan made to Viveve, the Company issued a 10-year Warrant to the Lender for the purchase of 471,698 shares of the Company’s common stock at an exercise price of $0.53 per share. The Warrant includes a cashless exercise provision.

 

The above are brief descriptions of the Loan Agreement, the Intellectual Property Security Agreement, the Unconditional Guaranty and the Warrant and are qualified in their entirety by the full text of those documents, which are attached as exhibits to this Current Report.

 

Item 2.03     Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information included in Item 1.01 above is incorporated herein by reference.

 

Item 3.02      Unregistered Sales of Equity Securities.

 

The information about the Warrant which is included in Item 1.01 above is incorporated herein by reference.

 

In issuing the Warrant, the Company relied on Section 4(a)(2) of the Securities Act of 1933, as amended, inasmuch as the Lender is an accredited investor and the Company did not engage in any form of general solicitation or general advertising in conjunction with the issuance of the Warrant.

 

 

 
 

 

 

Item 9.01     Financial Statements and Exhibits.

 

Exhibit No.

Description

   

10.1

Loan and Security Agreement dated as of September 30, 2014 between Viveve, Inc. and Square 1 Bank

10.2

Intellectual Property Security Agreement dated as of September 30, 2014 between Viveve, Inc. and Square 1 Bank

10.3

Unconditional Guaranty dated as of September 30, 2014 executed by Viveve Medical, Inc. in favor of Square 1 Bank

10.4

Warrant issued by Viveve Medical, Inc. in favor of Square 1 Bank

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

October 3, 2014

 

 

VIVEVE MEDICAL, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/  Scott Durbin

 

 

 

Scott Durbin, Chief Financial Officer

 

 

   

 
 

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

   

10.1

Loan and Security Agreement dated as of September 30, 2014 between Viveve, Inc. and Square 1 Bank

10.2

Intellectual Property Security Agreement dated as of September 30, 2014 between Viveve, Inc. and Square 1 Bank

10.3

Unconditional Guaranty dated as of September 30, 2014 executed by Viveve Medical, Inc. in favor of Square 1 Bank

10.4

Warrant issued by Viveve Medical, Inc. in favor of Square 1 Bank

 

Exhibit 10.1

 

VIVEVE, INC.

 

SQUARE 1 BANK

 

LOAN AND SECURITY AGREEMENT

 

 

 
 

 

 

This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of September 30, 2014, by and between Square 1 Bank (“Bank”) and VIVEVE, INC., a Delaware corporation (“Borrower”).

 

RECITALS

 

Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which Bank will advance credit to Borrower, and Borrower will repay the amounts owing to Bank.

 

AGREEMENT

 

The parties agree as follows:

 

1.      DEFINITIONS AND CONSTRUCTION .

 

1.1     Definitions . As used in this Agreement, all capitalized terms shall have the definitions set forth on Exhibit A. Any term used in the Code and not defined herein shall have the meaning given to the term in the Code.

 

1.2     Accounting Terms . Any accounting term not specifically defined on Exhibit A shall be construed in accordance with GAAP and all calculations shall be made in accordance with GAAP (except for non-compliance with FAS 123R in monthly reporting). The term “financial statements” shall include the accompanying notes and schedules.

 

2.      LOAN AND TERMS OF PAYMENT .

 

2.1     Credit Extensions .

 

(a)     Promise to Pay . Borrower promises to pay to Bank, in lawful money of the United States of America, the aggregate unpaid principal amount of all Credit Extensions made by Bank to Borrower, together with interest on the unpaid principal amount of such Credit Extensions at rates in accordance with the terms hereof.

 

(b)     Term Loan . Subject to and upon the terms and conditions of this Agreement, Bank agrees to make Term Loans to Borrower in an aggregate principal amount not to exceed Five Million Dollars ($5,000,000) in three tranches, as follows:

 

(i)     Tranche 1. Borrower shall request a Term Loan under Tranche 1 in the principal amount of Two Million Five Hundred Thousand Dollars ($2,500,000) as of the Closing Date. The Tranche 1 Advance shall be used to repay Borrower’s indebtedness to Oxford Finance LLC. Bank will credit any proceeds remaining after that payment to Borrower’s account with Bank.

 

(ii)     Tranche 2 . Borrower may request a Term Loan or Term Loans under Tranche 2 in the principal amount of up to One Million Five Hundred Thousand Dollars ($1,500,000) at any time during the period beginning on the date that Borrower has provided evidence acceptable to Bank of at least 50% enrollment in the OUS Clinical Trial and ending on January 31, 2015. The proceeds of the Tranche 2 Advances shall be used for general working capital purposes and for capital expenditures.

 

(iii)     Tranche 3. Borrower may request a Term Loan or Term Loans under Tranche 3 in the principal amount of up to One Million Dollars ($1,000,000) at any time during the period 1) beginning on the date that Borrower has provided evidence acceptable to Bank of (a) positive interim 3-month results from the OUS Clinical Trial and (b) a favorable call with 5am Ventures related to an additional investment in Borrower and 2) ending on June 30, 2015.  The proceeds of the Tranche 3 Advances shall be used for general working capital purposes and for capital expenditures.

 

 
1.

 

 

(iv)     Borrowing Notice . When Borrower desires to obtain a Term Loan, Borrower shall notify Bank (which notice shall be irrevocable) by electronic mail or facsimile transmission, to be received no later than 3:30 p.m. Eastern Time on the Business Day prior to the date on which the Term Loan is to be made.  Such notice shall be substantially in the form of Exhibit C.  The notice shall be signed by an Authorized Officer.

 

(v)     Repayment. Interest shall accrue from the date of each Term Loan at the rate specified in Section 2.3(a) or 2.3(b), as applicable, and shall be payable monthly beginning on the first day of the month following each such Term Loan, and continuing on the first day of each month thereafter for a period of twelve (12) months (the “Interest Only Period”). The principal balance of each Term Loan that is outstanding at the end of the applicable Interest Only Period shall be payable in 30 equal monthly installments of principal, plus all accrued interest, beginning on the first day of the first month following the end of the Interest Only Period, and continuing on the same day of each month thereafter through the Term Loan Maturity Date, at which time all amounts outstanding in connection with such Term Loan shall be immediately due and payable. Term Loans, once repaid, may not be reborrowed.

 

(vi)     Prepayment . Borrower may prepay all but not less than all of the Term Loans at any time, provided that Borrower may not reborrow any amount so prepaid, and provided further that upon any prepayment, including any prepayment required because of the occurrence of an Event of Default, Borrower shall pay, in addition to all outstanding principal and accrued interest on the Term Loans and the Final Payment, a prepayment fee equal to 2.0% of outstanding balance of the Term Loans if the prepayment occurs within 18 months of the Closing Date.

 

2.2     [Reserved.]

 

2.3     Interest Rates, Payments, and Calculations .

 

(a)     Term Loan Interest Rates .

 

(i)     Tranche 1 and Tranche 2 . Except as set forth in Section 2.3(b), the principal amount outstanding for the Tranche 1 Advance and each Tranche 2 Advance shall accrue interest at a fixed per annum rate equal to the Basic Rate in effect on the date of such Tranche 1 Advance or Tranche 2 Advance, respectively, plus the Applicable Margin, not in any case less than 5.0% per annum

 

(ii)     Tranche 3. Except as set forth in Section 2.3(b), the principal amount outstanding for each Tranche 3 Advance shall accrue interest at a fixed per annum rate equal to the Basic Rate in effect on the date of such Tranche 3 Advance plus the Applicable Margin, not in any case less than 6.5% per annum

 

(b)     Late Fee; Default Rate . If any payment is not made within 15 days after the date such payment is due, Borrower shall pay Bank a late fee equal to the lesser of (i) 5% of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. All Obligations shall bear interest, from and after the occurrence and during the continuance of an Event of Default, at a rate equal to 5 percentage points above the interest rate applicable immediately prior to the occurrence of the Event of Default.

 

(c)     Payments . Interest under the Term Loans shall be due and payable on the first calendar day of each month during the term hereof. Bank shall, at its option, charge such interest, all Bank Expenses, and all Periodic Payments against any of Borrower’s deposit accounts or against the Term Loans, in which case those amounts shall thereafter accrue interest at the rate then applicable hereunder. Any interest not paid when due shall be compounded by becoming a part of the Obligations, and such interest shall thereafter accrue interest at the rate then applicable hereunder.

 

(d)     Final Payment. Borrower shall make the Final Payment to Bank on account of each Term Loan on the earliest to occur of (a) the date that a Term Loan becomes due and payable, whether on the Term Loan Maturity Date or upon the occurrence of an Event of Default, or (b) the date that Borrower repays such Term Loan.

 

 
2.

 

 

(e)     Computation . All interest chargeable under the Loan Documents shall be computed on the basis of a 360 day year for the actual number of days elapsed.

 

2.4     Crediting Payments . Prior to the occurrence of an Event of Default, Bank shall credit a wire transfer of funds, check or other item of payment to such deposit account or Obligation as Borrower specifies, except that to the extent Borrower uses the Term Loans to purchase Collateral, Borrower’s repayment of the Term Loans shall apply on a “first-in-first-out” basis so that the portion of the Term Loans used to purchase a particular item of Collateral shall be paid in the chronological order the Borrower purchased the Collateral. After the occurrence and during the continuance of an Event of Default, Bank shall have the right, in its sole discretion, to immediately apply any wire transfer of funds, check, or other item of payment Bank may receive to conditionally reduce Obligations, but such applications of funds shall not be considered a payment on account unless such payment is of immediately available federal funds or unless and until such check or other item of payment is honored when presented for payment. Notwithstanding anything to the contrary contained herein, any wire transfer or payment received by Bank after 5:30 p.m. Eastern time shall be deemed to have been received by Bank as of the opening of business on the immediately following Business Day. Whenever any payment to Bank under the Loan Documents would otherwise be due (except by reason of acceleration) on a date that is not a Business Day, such payment shall instead be due on the next Business Day, and additional fees or interest, as the case may be, shall accrue and be payable for the period of such extension.

 

2.5     Fees . Borrower shall pay to Bank the following:

 

(a)     Facility Fee . None.

 

(b)     Bank Expenses . On the Closing Date, all Bank Expenses incurred through the Closing Date, and, after the Closing Date, all Bank Expenses, as and when they become due.

 

(c)     Final Payment . The Final Payment,.

 

2.6     Term . This Agreement shall become effective on the Closing Date and, subject to Section 12.7, shall continue in full force and effect for so long as any Obligations remain outstanding or Bank has any obligation to make Credit Extensions under this Agreement. Notwithstanding the foregoing, Bank shall have the right to terminate its obligation to make Credit Extensions under this Agreement immediately and without notice upon the occurrence and during the continuance of an Event of Default.

 

3.      CONDITIONS OF LOANS .

 

3.1     Conditions Precedent to Closing . The agreement of Bank to enter into this Agreement on the Closing Date is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, each the following items and completed each of the following requirements:

 

(a)      this Agreement;

 

(b)      an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution and delivery of this Agreement;

 

(c)      a financing statement (Form UCC-1);

 

(d)      an intellectual property security agreement;

 

(e)      payment of the fees and Bank Expenses then due specified in Section 2.5, which may be debited from any of Borrower’s accounts with Bank;

 

(f)      current SOS Reports indicating that except for Permitted Liens, there are no other security interests or Liens of record in the Collateral;

 

 
3.

 

 

(g)      current financial statements, including audited statements (or such other level required by the Investment Agreement) for Borrower’s most recently ended fiscal year, together with an unqualified opinion, or an opinion qualified only for going concern so long as Borrower’s investors provide additional equity as needed (Bank acknowledges that receipt of the equity referred to in Section 3.1(l) satisfies this condition), company prepared consolidated balance sheets, income statements and statements of cash flows for the most recently ended month in accordance with Section 6.2, and such other updated financial information as Bank may reasonably request;

 

(h)      current Compliance Certificate in accordance with Section 6.2;

 

(i)      a ten year warrant to purchase 471,698 shares of Parent common stock at an exercise price of $0.53 per share, in form and substance satisfactory to Bank;

 

(j)      a Guaranty;

 

(k)      a Borrower Information Certificate;

 

(l)      evidence of Borrower’s receipt of at least $6,000,000 in gross proceeds from the sale or issuance of equity securities of Parent, which amount may include conversion into equity of $1,500,000 of Subordinated Debt of Borrower in each case on terms reasonably acceptable to Bank;

 

(m)      evidence of the acceptance of the Certificate of Merger by the Delaware Secretary of State filed in connection with the Merger;

 

(n)      a payoff letter from Oxford Finance, LLC;

 

(o)      evidence that Borrower has deposited at least 50% of its Cash in accounts maintained with Bank; and

 

(p)      such other documents or certificates, and completion of such other matters, as Bank may reasonably request.

 

3.2     Conditions Precedent to all Credit Extensions . The obligation of Bank to make each Credit Extension, including the initial Credit Extension, is contingent upon the Borrower’s compliance with Section 3.1 above, and is further subject to the following conditions:

 

(a)      timely receipt by Bank of the Loan Advance/Paydown Request Form as provided in Section 2.1;

 

(b)      in Bank’s sole discretion, there has not been a Material Adverse Effect; and

 

(c)      the representations and warranties contained in Section 5 shall be true and correct in all material respects on and as of the date of such Loan Advance/Paydown Request Form and on the effective date of each Credit Extension as though made at and as of each such date, and no Event of Default shall have occurred and be continuing, or would exist after giving effect to such Credit Extension (provided, however, that those representations and warranties expressly referring to another date shall be true, correct and complete in all material respects as of such date). The making of each Credit Extension shall be deemed to be a representation and warranty by Borrower on the date of such Credit Extension as to the accuracy of the facts referred to in this Section 3.2.

 

4.      CREATION OF SECURITY INTEREST .

 

4.1     Grant of Security Interest . Borrower grants and pledges to Bank a continuing security interest in the Collateral to secure prompt repayment of any and all Obligations and to secure prompt performance by Borrower of each of its covenants and duties under the Loan Documents. Except for Permitted Liens or as disclosed in the Schedule, such security interest constitutes a valid, first priority security interest in the presently existing Collateral, and will constitute a valid, first priority security interest in later-acquired Collateral. Borrower also hereby agrees not to sell, transfer, assign, mortgage, pledge, lease, grant a security interest in, or encumber any of the Intellectual Property Collateral. Notwithstanding any termination of this Agreement or of any filings undertaken related to Bank’s rights under the Code, Bank’s Lien on the Collateral shall remain in effect for so long as any Obligations are outstanding.

 

 
4.

 

 

4.2     Perfection of Security Interest . Borrower authorizes Bank to file at any time financing statements, continuation statements, and amendments thereto that (i) either specifically describe the Collateral or describe the Collateral as all assets of Borrower of the kind pledged hereunder, and (ii) contain any other information required by the Code for the sufficiency of filing office acceptance of any financing statement, continuation statement, or amendment, including whether Borrower is an organization, the type of organization and any organizational identification number issued to Borrower, if applicable. Borrower shall have possession of the Collateral, except where expressly otherwise provided in this Agreement or where Bank chooses to perfect its security interest by possession in addition to the filing of a financing statement. Where Collateral is in possession of a third party bailee, Borrower shall take such steps as Bank reasonably requests for Bank to (i) subject to Section 7.10 below, obtain an acknowledgment, in form and substance satisfactory to Bank, of the bailee that the bailee holds such Collateral for the benefit of Bank, and (ii) obtain “control” of any Collateral consisting of investment property, deposit accounts, letter-of-credit rights or electronic chattel paper (as such items and the term “control” are defined in Revised Article 9 of the Code) by causing the securities intermediary or depositary institution or issuing bank to execute a control agreement in form and substance satisfactory to Bank. Borrower will not create any chattel paper without placing a legend on the chattel paper acceptable to Bank indicating that Bank has a security interest in the chattel paper. Borrower from time to time may deposit with Bank specific cash collateral to secure specific Obligations; Borrower authorizes Bank to hold such specific balances in pledge and to decline to honor any drafts thereon or any request by Borrower or any other Person to pay or otherwise transfer any part of such balances for so long as the specific Obligations are outstanding. Borrower shall take such other actions as Bank requests to perfect its security interests granted under this Agreement.

 

5.      REPRESENTATIONS AND WARRANTIES .

 

Borrower represents and warrants as follows:

 

5.1     Due Organization and Qualification . Borrower and each Subsidiary is duly existing under the laws of the state in which it is organized and qualified and licensed to do business in any state in which the conduct of its business or its ownership of property requires that it be so qualified, except where the failure to do so would not reasonably be expected to cause a Material Adverse Effect.

 

5.2     Due Authorization; No Conflict . The execution, delivery, and performance of the Loan Documents are within Borrower’s powers, have been duly authorized, and are not in conflict with nor constitute a breach of any provision contained in Borrower’s Certificate of Incorporation or Bylaws, nor will they constitute an event of default under any material agreement by which Borrower is bound. Borrower is not in default under any agreement by which it is bound, except to the extent such default would not reasonably be expected to cause a Material Adverse Effect.

 

5.3     Collateral . Borrower has rights in or the power to transfer the Collateral, and, except as included on Schedule 5.3, its title to the Collateral is free and clear of Liens, adverse claims, and restrictions on transfer or pledge except for Permitted Liens. Other than movable items of personal property such as laptop computers, all Collateral having an aggregate book value in excess of $100,000 is located solely in the Collateral States. All Inventory is in all material respects of good and merchantable quality, free from all material defects, except for Inventory for which adequate reserves have been made. Except as set forth in the Schedule, none of the Borrower’s Cash is maintained or invested with a Person other than Bank or Bank’s affiliates.

 

5.4     Intellectual Property Collateral . Borrower’s Intellectual Property Collateral is set forth on Schedule 5.4 hereto. Borrower is the sole owner of the Intellectual Property Collateral, except for licenses granted by Borrower to its customers in the ordinary course of business. To the best of Borrower’s knowledge, each of the Copyrights, Trademarks and Patents is valid and enforceable, and no part of the Intellectual Property Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made to Borrower that any part of the Intellectual Property Collateral violates the rights of any third party except to the extent such claim would not reasonably be expected to cause a Material Adverse Effect.

 

 
5.

 

 

5.5     Name; Location of Chief Executive Office . Except as disclosed in the Schedule, Borrower has not done business under any name other than that specified on the signature page hereof, and its exact legal name is as set forth in the first paragraph of this Agreement. The chief executive office of Borrower is located at the address indicated in Section 10 hereof.

 

5.6     Litigation . Except as set forth in the Schedule, there are no actions or proceedings pending by or against Borrower or any Subsidiary before any court or administrative agency in which a likely adverse decision would reasonably be expected to have a Material Adverse Effect.

 

5.7     No Material Adverse Change in Financial Statements . All consolidated and to the extent prepared by Borrower, consolidating financial statements related to Borrower and any Subsidiary that are delivered by Borrower to Bank fairly present in all material respects Borrower’s consolidated and to the extent prepared by Borrower, consolidating financial condition as of the date thereof and Borrower’s consolidated and to the extent prepared by Borrower, consolidating results of operations for the period then ended. There has not been a material adverse change in the consolidated and to the extent prepared by Borrower, consolidating financial condition of Borrower since the date of the most recent of such financial statements submitted to Bank.

 

5.8     Solvency, Payment of Debts . Borrower is able to pay its debts (including trade debts) as they mature; the fair saleable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; and Borrower is not left with unreasonably small capital after the transactions contemplated by this Agreement.

 

5.9     Compliance with Laws and Regulations . Borrower and each Subsidiary have met the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. No event has occurred resulting from Borrower’s failure to comply with ERISA that is reasonably likely to result in Borrower’s incurring any liability that could have a Material Adverse Effect. Borrower is not an “investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940. Borrower is not engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations T and U of the Board of Governors of the Federal Reserve System). Borrower has not violated any statutes, laws, ordinances or rules applicable to it, the violation of which would reasonably be expected to have a Material Adverse Effect. Borrower and each Subsidiary have filed or caused to be filed all tax returns required to be filed, and have paid, or have made adequate provision for the payment of, all taxes reflected therein except those being contested in good faith with adequate reserves under GAAP or where the failure to file such returns or pay such taxes would not reasonably be expected to have a Material Adverse Effect.

 

5.10     Subsidiaries . Borrower does not own any stock, partnership interest or other equity securities of any Person, except for Permitted Investments.

 

5.11     Government Consents . Borrower and each Subsidiary have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all governmental authorities that are necessary for the continued operation of Borrower’s business as currently conducted, except where the failure to do so would not reasonably be expected to cause a Material Adverse Effect.

 

5.12     Inbound Licenses . Except as disclosed on the Schedule, Borrower is not a party to, nor is bound by, any material license or other agreement important for the conduct of Borrower’s business that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or any other property important for the conduct of Borrower’s business, other than this Agreement or the other Loan Documents.

 

 
6.

 

 

5.13     Full Disclosure . No representation, warranty or other statement made by Borrower in any certificate or written statement furnished to Bank taken together with all such certificates and written statements furnished to Bank contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained in such certificates or statements not misleading in light of the circumstances in which they were made, it being recognized by Bank that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not to be viewed as facts and that actual results during the period or periods covered by any such projections and forecasts may differ from the projected or forecasted results.

 

6.      AFFIRMATIVE COVENANTS .

 

Borrower covenants that, until payment in full of all outstanding Obligations, and for so long as Bank may have any commitment to make a Credit Extension hereunder, Borrower shall do all of the following:

 

6.1     Good Standing and Government Compliance . Borrower shall maintain its and each of its Subsidiaries’ corporate existence and good standing in the respective states of formation, shall maintain qualification and good standing in each other jurisdiction in which the failure to so qualify would reasonably be expected to have a Material Adverse Effect, and shall furnish to Bank the organizational identification number issued to Borrower by the authorities of the state in which Borrower is organized, if applicable. Borrower shall meet, and shall cause each Subsidiary to meet, the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. Borrower shall comply, and shall cause each Subsidiary to comply, with all statutes, laws, ordinances and government rules and regulations to which it is subject, and shall maintain, and shall cause each of its Subsidiaries to maintain, in force all licenses, approvals and agreements, the loss of which or failure to comply with which would reasonably be expected to have a Material Adverse Effect.

 

6.2     Financial Statements, Reports, Certificates . Borrower shall deliver to Bank: (i) as soon as available, but in any event within 30 days after the end of each calendar month, a company prepared consolidated (and to the extent prepared by Borrower, consolidating) balance sheet, income statement, and statement of cash flows covering Borrower’s operations during such period, together with an aging of accounts receivable and payable, each in a form reasonably acceptable to Bank and certified by a Responsible Officer; (ii) as soon as available, but in any event within 180 days after the end of Borrower’s fiscal year, audited (or such other level as is required by the Investment Agreement) financial statements of Parent, consolidating Borrower’s financial information, prepared in accordance with GAAP, consistently applied, together with an opinion which is either unqualified or qualified only for going concern on such financial statements of an independent certified public accounting firm reasonably acceptable to Bank; (iii) annual budget approved by Borrower’s Board of Directors as soon as available but not later than January 15 th of each year during the term of this Agreement; (iv) if applicable, copies of all statements, reports and notices sent or made available generally by Borrower to its security holders or to any holders of Subordinated Debt and all reports on Forms 10-K and 10-Q filed by Parent with the Securities and Exchange Commission (the “SEC”), provided, however, that any report, including Parent’s reports on Forms 10-K and 10-Q, required to be filed by Parent with the SEC pursuant to Sections 13 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), shall be deemed to have been delivered to Bank so long as such reports are available for viewing either at Parent’s website or at the SEC’s website, www.sec.gov; (v) promptly upon receipt of notice thereof, a report of any legal actions pending or threatened against Borrower or any Subsidiary that could reasonably be expected to result in damages or costs to Borrower or any Subsidiary of $100,000 or more; (vi) promptly upon receipt, each management letter prepared by Parent’s independent certified public accounting firm regarding Parent’s management control systems; (vii) such budgets, sales projections, operating plans or other financial information as Bank may reasonably request from time to time; and (viii) within 30 days of the last day of each fiscal quarter, a report signed by Borrower, in form reasonably acceptable to Bank, listing any applications or registrations that Borrower has made or filed in respect of any Patents, Copyrights or Trademarks and the status of any outstanding applications or registrations, as well as any material change in Borrower’s Intellectual Property Collateral, including but not limited to any subsequent ownership right of Borrower in or to any Trademark, Patent or Copyright not specified in Exhibits A, B, and C of any Intellectual Property Security Agreement delivered to Bank by Borrower in connection with this Agreement.

 

(a)      Within 30 days after the last day of each month, Borrower shall deliver to Bank with the monthly financial statements a Compliance Certificate certified as of the last day of the applicable month and signed by a Responsible Officer in substantially the form of Exhibit D hereto.

 

 
7.

 

 

(b)      As soon as possible and in any event within 3 calendar days after becoming aware of the occurrence or existence of an Event of Default hereunder, a written statement of a Responsible Officer setting forth details of the Event of Default, and the action which Borrower has taken or proposes to take with respect thereto.

 

(c)      Bank (through any of its officers, employees, or agents) shall have the right, upon reasonable prior notice, from time to time during Borrower’s usual business hours but no more than twice a year (unless an Event of Default has occurred and is continuing), to inspect Borrower’s Books and to make copies thereof and to check, test, inspect, audit and appraise the Collateral at Borrower’s expense in order to verify Borrower’s financial condition or the amount, condition of, or any other matter relating to, the Collateral.

 

(d)      Upon Bank’s request, updates as to any of Borrower’s clinical trials in detail reasonably acceptable to Bank.

 

Borrower may deliver to Bank on an electronic basis any certificates, reports or information required pursuant to this Section 6.2, and Bank shall be entitled to rely on the information contained in the electronic files, provided that Bank in good faith believes that the files were delivered by a Responsible Officer. Borrower shall include a submission date on any certificates and reports to be delivered electronically.

 

6.3     Inventory and Equipment; Returns . Borrower shall keep all Inventory and Equipment in good and merchantable condition, free from all material defects except for Inventory and Equipment (i) sold in the ordinary course of business, and (ii) for which adequate reserves have been made, in all cases in the United States and such other locations as to which Borrower gives prior written notice. Returns and allowances, if any, as between Borrower and its account debtors shall be on the same basis and in accordance with the usual customary practices of Borrower, as they exist on the Closing Date. Borrower shall promptly notify Bank of all returns and recoveries and of all disputes and claims involving inventory having a book value of more than $100,000.

 

6.4     Taxes . Borrower shall make, and cause each Subsidiary to make, due and timely payment or deposit of all material federal, state, and local taxes, assessments, or contributions required of it by law, including, but not limited to, those laws concerning income taxes, F.I.C.A., F.U.T.A. and state disability, and will execute and deliver to Bank, on demand, proof satisfactory to Bank indicating that Borrower or a Subsidiary has made such payments or deposits and any appropriate certificates attesting to the payment or deposit thereof; provided that Borrower or a Subsidiary need not make any payment if the amount or validity of such payment is contested in good faith by appropriate proceedings and is reserved against (to the extent required by GAAP) by Borrower or such Subsidiary.

 

6.5     Insurance . Borrower, at its expense, shall (i) keep the Collateral insured against loss or damage, and (ii) maintain liability and other insurance, in each case as ordinarily insured against by other owners in businesses similar to Borrower’s. All such policies of insurance shall be in such form, with such companies, and in such amounts as reasonably satisfactory to Bank. All policies of property insurance shall contain a lender’s loss payable endorsement, in a form satisfactory to Bank, showing Bank as an additional loss payee, and all liability insurance policies shall show Bank as an additional insured and specify that the insurer must give at least 20 days notice to Bank before canceling its policy for any reason. Within 30 days of the Closing Date, Borrower shall cause to be furnished to Bank a copy of its policies or certificate of insurance including any endorsements covering Bank or showing Bank as an additional insured. Upon Bank’s request, Borrower shall deliver to Bank certified copies of the policies of insurance and evidence of all premium payments. Proceeds payable under any casualty policy will, at Borrower’s option, be payable to Borrower to replace the property subject to the claim, provided that any such replacement property shall be deemed Collateral in which Bank has been granted a first priority security interest, provided that if an Event of Default has occurred and is continuing, all proceeds payable under any such policy shall, at Bank’s option, be payable to Bank to be applied on account of the Obligations.

 

6.6     Primary Depository . Borrower shall maintain its primary investment accounts with Bank or Bank’s affiliates; provided that prior to maintaining any investment accounts with Bank’s affiliates, Borrower, Bank, and any such affiliate shall have entered into a securities account control agreement with respect to any such investment accounts, in form and substance satisfactory to Bank. Borrower shall open and fund its account with Bank or its Affiliate before the Closing Date with at least half of Borrower’s Cash, and shall have 30 days after the Closing Date to move substantially all of the rest of its Cash to Bank or its Affiliate.

 

 
8.

 

 

6.7     Financial Covenants. Borrower shall satisfy the following covenants and meet the following milestones:

 

(a)     Performance to Plan . Beginning with the month ending September 30, 2015, the two-month period ending October 31, 2015, the three-month period ending November 30, 2015, and measured on a trailing three-month basis thereafter, Borrower shall achieve Revenue of not less than 80% of that set forth on the attachment to the Schedule hereto. Borrower shall deliver to Bank updated projections approved by Borrower’s Board of Directors for the next fiscal year not less than 30 days prior to the end of Borrower’s current fiscal year.

 

(b)     OUS Clinical Trial Milestones .

 

(i)      Receive by March 31, 2015 evidence of full enrollment in the OUS Clinical Trial.

 

(ii)      Receive by April 30, 2015 evidence of positive 3-month interim data in the OUS Clinical Trial.

 

(iii)      Receive by January 31, 2016 evidence of positive results from the OUS Clinical Trial.

 

(c)     Minimum Equity Event . Receive New Equity in an amount mutually acceptable to the Board of Borrower and Bank no later than October 31, 2015.

 

6.8     Registration of Intellectual Property Rights .

 

(a)      Borrower shall promptly give Bank written notice of any applications or registrations of intellectual property rights filed with the United States Patent and Trademark Office, including the date of such filing and the registration or application numbers, if any.

 

(b)      Borrower shall (i) give Bank not less than 15 days prior written notice of the filing of any applications or registrations with the United States Copyright Office, including the title of such intellectual property rights to be registered, as such title will appear on such applications or registrations, and the date such applications or registrations will be filed; (ii) prior to the filing of any such applications or registrations, execute such documents as Bank may reasonably request for Bank to maintain its perfection in such intellectual property rights to be registered by Borrower; (iii) upon the request of Bank, either deliver to Bank or file such documents simultaneously with the filing of any such applications or registrations; (iv) upon filing any such applications or registrations, promptly provide Bank with a copy of such applications or registrations together with any exhibits, evidence of the filing of any documents requested by Bank to be filed for Bank to maintain the perfection and priority of its security interest in such intellectual property rights, and the date of such filing.

 

(c)      Borrower shall execute and deliver such additional instruments and documents from time to time as Bank shall reasonably request to perfect and maintain the perfection and priority of Bank’s security interest in the Intellectual Property Collateral.

 

(d)      Borrower shall use commercially reasonable efforts to (i) protect, defend and maintain the validity and enforceability of the trade secrets, Trademarks, Patents and Copyrights, (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Bank in writing of material infringements detected and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public without the written consent of Bank, which shall not be unreasonably withheld.

 

(e)      Bank shall have the right, but not the obligation, to take, at Borrower’s sole expense, any actions that Borrower is required under this Section 6.8 to take but which Borrower fails to take, after 15 days’ notice to Borrower. Borrower shall reimburse and indemnify Bank for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this Section 6.8.

 

 
9.

 

 

6.9     Consent of Inbound Licensors . Prior to entering into or becoming bound by any material inbound license or agreement, Borrower shall: (i) provide written notice to Bank of the material terms of such license or agreement with a description of its likely impact on Borrower’s business or financial condition; and (ii) in good faith use commercially reasonable efforts to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for Borrower’s interest in such licenses or contract rights to be deemed Collateral and for Bank to have a security interest in it which might otherwise be restricted by the terms of the applicable license or agreement, whether now existing or entered into in the future, provided, however, that the failure to obtain any such consent or waiver shall not constitute a default under this Agreement.

 

6.10      Creation/Acquisition of Subsidiaries. In the event Borrower or any Subsidiary of Borrower creates or acquires any Subsidiary, Borrower or such Subsidiary shall promptly notify Bank of such creation or acquisition, and Borrower or such Subsidiary shall take all actions reasonably requested by Bank to achieve any of the following with respect to such “ New Subsidiary ” (defined as a Subsidiary formed after the date hereof during the term of this Agreement):  (i) to cause New Subsidiary to become either a co-Borrower hereunder, if such New Subsidiary is organized under the laws of the United States, or a secured guarantor with respect to the Obligations; and (ii) to grant and pledge to Bank a perfected security interest in 100% of the stock, units or other evidence of ownership held by Borrower or its Subsidiaries of any such New Subsidiary which is organized under the laws of the United States, and 65% of the stock, units or other evidence of ownership held by Borrower or its Subsidiaries of any such New Subsidiary which is not organized under the laws of the United States.

 

6.11     Further Assurances . At any time and from time to time Borrower shall execute and deliver such further instruments and take such further action as may reasonably be requested by Bank to effect the purposes of this Agreement.

 

7.      NEGATIVE COVENANTS .

 

Borrower covenants and agrees that, so long as any credit hereunder shall be available and until the outstanding Obligations are paid in full or for so long as Bank may have any commitment to make any Credit Extensions, Borrower will not do any of the following without Bank’s prior written consent, which shall not be unreasonably withheld:

 

7.1     Dispositions . Convey, sell, lease, license, transfer or otherwise dispose of (collectively, to “ Transfer ”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, or move cash balances on deposit with Bank to accounts opened at another financial institution, other than Permitted Transfers.

 

7.2     Change in Name, Location, Executive Office, or Executive Management; Change in Business; Change in Fiscal Year; Change in Control . Change its name or the state of Borrower’s formation or relocate its chief executive office without 30 days prior written notification to Bank; replace its chief executive officer or chief financial officer without delivering written notification to Bank within 10 days following the resignation or other termination of the chief executive officer or chief financial officer; fail to appoint an interim replacement or fill a vacancy in the position of chief executive officer or chief financial officer for more than 45 consecutive days; or suffer the resignation of one or more directors from its board of directors in anticipation of the Borrower’s insolvency without the prior written consent of Bank,. which may be withheld in Bank's sole discretion, take action to liquidate, wind up, or otherwise cease to conduct business in the ordinary course; engage in any business, or permit any of its Subsidiaries to engage in any business, other than or reasonably related or incidental to the businesses currently engaged in by Borrower; change its fiscal year end; have a Change in Control.

 

7.3     Mergers or Acquisitions . Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person except where (a) each of the following conditions is applicable: (i) the consideration paid in connection with such transactions (including assumption of liabilities) does not in the aggregate exceed $100,000 during any fiscal year, (ii) no Event of Default has occurred, is continuing or would exist after giving effect to such transactions, (iii) such transactions do not result in a Change in Control, and (iv) Borrower is the surviving entity; or (b) the Obligations are repaid in full concurrently with the closing of any merger or consolidation of Borrower in which Borrower is not the surviving entity; provided, however, that Borrower shall not, without Bank’s prior written consent, enter into any  binding contractual arrangement with any Person to attempt to facilitate a merger or acquisition of Borrower, unless (i) no Event of Default exists when such agreement is entered into by Borrower, (ii)  such agreement does not give such Person the right to claim any fee, payment or damages from any parties, other than from Borrower or Borrower's investors, in connection with a sale of Borrower's stock or assets pursuant to or resulting from an assignment for the benefit of creditors, an asset turnover to Borrower's creditors (including, without limitation, Bank), foreclosure, bankruptcy or similar liquidation, and (iii) Borrower notifies Bank in advance of entering into such an agreement (provided, the failure to give such notification shall not be deemed a material breach of this Agreement).

 

 
10.

 

 

7.4     Indebtedness . Create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except Indebtedness to Bank.

 

7.5     Encumbrances . Create, incur, assume or allow any Lien with respect to its property, or assign or otherwise convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries so to do, except for Permitted Liens, or covenant to any other Person (other than (i) the licensors of in-licensed property with respect to such property or (ii) the lessors of specific equipment or lenders financing specific equipment with respect to such leased or financed equipment) that Borrower in the future will refrain from creating, incurring, assuming or allowing any Lien with respect to any of Borrower’s property.

 

7.6     Distributions . Pay any dividends or make any other distribution or payment on account of or in redemption, retirement or purchase of any capital stock, except that Borrower may (i) repurchase the stock of former employees or directors pursuant to stock repurchase agreements in an aggregate amount not to exceed $150,000 in any fiscal year, so long as an Event of Default does not exist prior to such repurchase or would not exist after giving effect to such repurchase, and (ii) repurchase the stock of former employees or directors pursuant to stock repurchase agreements in any amount where the consideration for the repurchase is the cancellation of indebtedness owed by such former employees or directors to Borrower regardless of whether an Event of Default exists.

 

7.7     Investments . Directly or indirectly acquire or own an Investment in, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do, other than Permitted Investments, or maintain or invest any of its investment property with a Person other than Bank or permit any Subsidiary to do so unless such Person has entered into a control agreement with Bank, in form and substance satisfactory to Bank, or suffer or permit any Subsidiary to be a party to, or be bound by, an agreement that restricts such Subsidiary from paying dividends or otherwise distributing property to Borrower.

 

7.8     Transactions with Affiliates . Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower except for transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person.

 

7.9     Subordinated Debt . Make any payment in respect of any Subordinated Debt, or permit any of its Subsidiaries to make any such payment, except in compliance with the terms of such Subordinated Debt, or amend any provision affecting Bank’s rights contained in any documentation relating to the Subordinated Debt without Bank’s prior written consent.

 

7.10     Inventory and Equipment . Store the Inventory or the Equipment of a book value in excess of $100,000 with a bailee, warehouseman, collocation facility or similar third party unless the third party has been notified of Bank’s security interest and Bank (a) has received an acknowledgment from the third party that it is holding or will hold the Inventory or Equipment for Bank’s benefit or (b) is in possession of the warehouse receipt, where negotiable, covering such Inventory or Equipment. Except for Inventory sold in the ordinary course of business and for movable items of personal property having an aggregate book value not in excess of $100,000, and except for such other locations as Bank may approve in writing, Borrower shall keep the Inventory and Equipment only at the location set forth in Section 10 and such other locations of which Borrower gives Bank prior written notice and as to which Bank is able to take such actions as may be necessary to perfect its security interest or to obtain a bailee’s acknowledgment of Bank’s rights in the Collateral.

 

 
11.

 

 

7.11     No Investment Company; Margin Regulation . Become or be controlled by an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of its important activities, the business of extending credit for the purpose of purchasing or carrying margin stock, or use the proceeds of any Credit Extension for such purpose.

 

8.      EVENTS OF DEFAULT .

 

Any one or more of the following events shall constitute an Event of Default by Borrower under this Agreement:

 

8.1     Payment Default . If Borrower fails to pay any of the Obligations when due;

 

8.2     Covenant Default .

 

(a)      If Borrower fails to perform any obligation under Sections 6.2 (financial reporting), 6.4 (taxes), 6.5 (insurance), 6.6 (primary accounts) or 6.7 (financial covenants), or violates any of the covenants contained in Article 7 of this Agreement; or

 

(b)      If Borrower fails or neglects to perform or observe any other material term, provision, condition, covenant contained in this Agreement, in any of the Loan Documents, or in any other present or future agreement between Borrower and Bank and as to any default under such other term, provision, condition or covenant that can be cured, has failed to cure such default within 10 days after Borrower receives notice thereof or any officer of Borrower becomes aware thereof; provided, however, that if the default cannot by its nature be cured within the 10 day period or cannot after diligent attempts by Borrower be cured within such 10 day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional reasonable period (which shall not in any case exceed 30 days) to attempt to cure such default, and within such reasonable time period the failure to have cured such default shall not be deemed an Event of Default but no Credit Extensions will be made;

 

8.3     Material Adverse Change . If there occurs any circumstance or any circumstances which would reasonably be expected to have a Material Adverse Effect;

 

8.4     Attachment . If any material portion of Borrower’s assets is attached, seized, subjected to a writ or distress warrant, or is levied upon, or comes into the possession of any trustee, receiver or person acting in a similar capacity and such attachment, seizure, writ or distress warrant or levy has not been removed, discharged or rescinded within 20 days, or if Borrower is enjoined, restrained, or in any way prevented by court order from continuing to conduct all or any material part of its business affairs, or if a judgment or other claim becomes a lien or encumbrance upon any material portion of Borrower’s assets, or if a notice of lien, levy, or assessment is filed of record with respect to any material portion of Borrower’s assets by the United States Government, or any department, agency, or instrumentality thereof, or by any state, county, municipal, or governmental agency, and the same is not paid within ten days after Borrower receives notice thereof, provided that none of the foregoing shall constitute an Event of Default where such action or event is stayed or an adequate bond has been posted pending a good faith contest by Borrower (provided that no Credit Extensions will be made during such cure period);

 

8.5     Insolvency . If Borrower becomes insolvent, or if an Insolvency Proceeding is commenced by Borrower, or if an Insolvency Proceeding is commenced against Borrower and is not dismissed or stayed within 30 days (provided that no Credit Extensions will be made prior to the dismissal of such Insolvency Proceeding);

 

 
12.

 

 

8.6     Other Agreements . If there is a default or other failure to perform in any agreement to which Borrower is a party with a third party or parties (a) resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of $100,000, (b) in connection with any lease for real property related to the Borrower’s principal place of business which results in the ability of the landlord to terminate such lease, or (c) that would reasonably be expected to have a Material Adverse Effect;

 

8.7     Judgments . If a final, uninsured judgment or judgments for the payment of money in an amount, individually or in the aggregate, of at least $100,000 shall be rendered against Borrower and shall remain unsatisfied and unstayed for a period of 45 days (provided that no Credit Extensions will be made prior to the satisfaction or stay of the judgment); or

 

8.8     Misrepresentations . If any material misrepresentation or material misstatement exists now or hereafter in any warranty or representation set forth herein or in any certificate delivered to Bank by any Responsible Officer pursuant to this Agreement or to induce Bank to enter into this Agreement or any other Loan Document.

 

9.      BANK’S RIGHTS AND REMEDIES .

 

9.1     Rights and Remedies . Upon the occurrence and during the continuance of an Event of Default, Bank may, at its election, without notice of its election and without demand, do any one or more of the following, all of which are authorized by Borrower:

 

(a)      Declare all Obligations, whether evidenced by this Agreement, by any of the other Loan Documents, or otherwise, immediately due and payable (provided that upon the occurrence of an Event of Default described in Section 8.5 (insolvency), all Obligations shall become immediately due and payable without any action by Bank);

 

(b)      Cease advancing money or extending credit to or for the benefit of Borrower under this Agreement or under any other agreement between Borrower and Bank;

 

(c)      Settle or adjust disputes and claims directly with account debtors for amounts, upon terms and in whatever order that Bank reasonably considers advisable;

 

(d)      Make such payments and do such acts as Bank considers necessary or reasonable to protect its security interest in the Collateral. Borrower agrees to assemble the Collateral if Bank so requires, and to make the Collateral available to Bank as Bank may designate. Borrower authorizes Bank to enter the premises where the Collateral is located, to take and maintain possession of the Collateral, or any part of it, and to pay, purchase, contest, or compromise any encumbrance, charge, or lien which in Bank’s determination appears to be prior or superior to its security interest and to pay all expenses incurred in connection therewith. With respect to any of Borrower’s owned premises, Borrower hereby grants Bank a license to enter into possession of such premises and to occupy the same, without charge, in order to exercise any of Bank’s rights or remedies provided herein, at law, in equity, or otherwise;

 

(e)      Set off and apply to the Obligations any and all (i) balances and deposits of Borrower held by Bank, and (ii) indebtedness at any time owing to or for the credit or the account of Borrower held by Bank;

 

(f)      Ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell (in the manner provided for herein) the Collateral. Bank is hereby granted a license or other right, solely pursuant to the provisions of this Section 9.1, to use, without charge, Borrower’s labels, patents, copyrights, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any property of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Bank’s exercise of its rights under this Section 9.1, Borrower’s rights under all licenses and all franchise agreements shall inure to Bank’s benefit;

 

 
13.

 

 

(g)      Sell the Collateral at either a public or private sale, or both, by way of one or more contracts or transactions, for cash or on terms, in such manner and at such places (including Borrower’s premises) as Bank determines is commercially reasonable, and apply any proceeds to the Obligations in whatever manner or order Bank deems appropriate. Bank may sell the Collateral without giving any warranties as to the Collateral. Bank may specifically disclaim any warranties of title or the like. This procedure will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral. If Bank sells any of the Collateral upon credit, Borrower will be credited only with payments actually made by the purchaser, received by Bank, and applied to the indebtedness of the purchaser. If the purchaser fails to pay for the Collateral, Bank may resell the Collateral and Borrower shall be credited with the proceeds of the sale;

 

(h)      Bank may credit bid and purchase at any public sale;

 

(i)      Apply for the appointment of a receiver, trustee, liquidator or conservator of the Collateral, without notice and without regard to the adequacy of the security for the Obligations and without regard to the solvency of Borrower, any guarantor or any other Person liable for any of the Obligations; and

 

(j)      Any deficiency that exists after disposition of the Collateral as provided above will be paid immediately by Borrower.

 

Bank may comply with any applicable state or federal law requirements in connection with a disposition of the Collateral and compliance will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral.

 

9.2     Power of Attorney . Effective only upon the occurrence and during the continuance of an Event of Default, Borrower hereby irrevocably appoints Bank (and any of Bank’s designated officers, or employees) as Borrower’s true and lawful attorney to: (a) send requests for verification of Accounts or notify account debtors of Bank’s security interest in the Accounts; (b) endorse Borrower’s name on any checks or other forms of payment or security that may come into Bank’s possession; (c) sign Borrower’s name on any invoice or bill of lading relating to any Account, drafts against account debtors, schedules and assignments of Accounts, verifications of Accounts, and notices to account debtors; (d) dispose of any Collateral; (e) make, settle, and adjust all claims under and decisions with respect to Borrower’s policies of insurance; (f) settle and adjust disputes and claims respecting the accounts directly with account debtors, for amounts and upon terms which Bank determines to be reasonable; (g) enter into a short-form intellectual property security agreement consistent with the terms of this Agreement for recording purposes only or modify, in its sole discretion, any intellectual property security agreement entered into between Borrower and Bank without first obtaining Borrower’s approval of or signature to such modification by amending Exhibits A, B, and C, thereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Borrower after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Borrower no longer has or claims to have any right, title or interest; and (h) file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral; provided Bank may exercise such power of attorney to sign the name of Borrower on any of the documents described in clauses (g) and (h) above, regardless of whether an Event of Default has occurred. The appointment of Bank as Borrower’s attorney in fact, and each and every one of Bank’s rights and powers, being coupled with an interest, is irrevocable until all of the Obligations have been fully repaid and performed and Bank’s obligation to provide advances hereunder is terminated.

 

9.3     Accounts Collection . At any time after the occurrence and during the continuation of an Event of Default, Bank may notify any Person owing funds to Borrower of Bank’s security interest in such funds and verify the amount of such Account. Borrower shall collect all amounts owing to Borrower for Bank, receive in trust all payments as Bank’s trustee, and immediately deliver such payments to Bank in their original form as received from the account debtor, with proper endorsements for deposit.

 

9.4     Bank Expenses . If Borrower fails to pay any amounts or furnish any required proof of payment due to third persons or entities, as required under the terms of this Agreement, then Bank may do any or all of the following after reasonable notice to Borrower: (a) make payment of the same or any part thereof; or (b) obtain and maintain insurance policies of the type discussed in Section 6.5 of this Agreement, and take any action with respect to such policies as Bank deems prudent. Any amounts so paid or deposited by Bank shall constitute Bank Expenses, shall be immediately due and payable, and shall bear interest at the then applicable rate hereinabove provided, and shall be secured by the Collateral. Any payments made by Bank shall not constitute an agreement by Bank to make similar payments in the future or a waiver by Bank of any Event of Default under this Agreement.

 

 
14.

 

 

9.5     Bank’s Liability for Collateral . Bank has no obligation to clean up or otherwise prepare the Collateral for sale. All risk of loss, damage or destruction of the Collateral shall be borne by Borrower.

 

9.6     No Obligation to Pursue Others . Bank has no obligation to attempt to satisfy the Obligations by collecting them from any other person liable for them and Bank may release, modify or waive any collateral provided by any other Person to secure any of the Obligations, all without affecting Bank’s rights against Borrower. Borrower waives any right it may have to require Bank to pursue any other Person for any of the Obligations.

 

9.7     Remedies Cumulative . Bank’s rights and remedies under this Agreement, the Loan Documents, and all other agreements shall be cumulative. Bank shall have all other rights and remedies not inconsistent herewith as provided under the Code, by law, or in equity. No exercise by Bank of one right or remedy shall be deemed an election, and no waiver by Bank of any Event of Default on Borrower’s part shall be deemed a continuing waiver. No delay by Bank shall constitute a waiver, election, or acquiescence by it. No waiver by Bank shall be effective unless made in a written document signed on behalf of Bank and then shall be effective only in the specific instance and for the specific purpose for which it was given. Borrower expressly agrees that this Section 9.7 may not be waived or modified by Bank by course of performance, conduct, estoppel or otherwise.

 

9.8     Demand; Protest . Except as otherwise provided in this Agreement, Borrower waives demand, protest, notice of protest, notice of default or dishonor, notice of payment and nonpayment and any other notices relating to the Obligations.

 

10.      NOTICES .

 

Unless otherwise provided in this Agreement, all notices or demands by any party relating to this Agreement or any other agreement entered into in connection herewith shall be in writing and (except for financial statements and other informational documents which may be sent by first-class mail, postage prepaid) shall be personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return receipt requested, or by telefacsimile to Borrower or to Bank, as the case may be, at its addresses set forth below:

 

If to Borrower:                                      VIVEVE, INC.

150 Commercial Street

Sunnyvale, CA 94086

Attn: Scott C. Durbin, CFO

FAX: (408) 530-1919 

 

With a copy to:                                    Richardson & Patel, LLP

1100 Glendon Avenue

Suite 850

Los Angeles, CA 90024

Attn: Kevin Friedmann, Esq.

FAX: (310) 208-1154

 

If to Bank:                                             Square 1 Bank

406 Blackwell Street, Suite 240

Durham, North Carolina 27701

Attn: Loan Operations Manager

FAX: (919) 314-3080

 

with a copy to:                                     Square 1 Bank

500 Second Street, Second Floor

San Francisco, CA 94107

Attn: Ben Colombo

FAX: (___) _______________

 

 
15.

 

 

The parties hereto may change the address at which they are to receive notices hereunder, by notice in writing in the foregoing manner given to the other.

 

11.      CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER .

 

This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of California, without regard to principles of conflicts of law. Jurisdiction shall lie in the State of California. All disputes, controversies, claims, actions and similar proceedings arising with respect to Borrower’s account or any related agreement or transaction shall be brought in the Superior Court of San Mateo County, California or the United States District Court for the Northern District of California, except as provided below with respect to arbitration of such matters. BANK AND BORROWER EACH ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED. EACH OF THEM, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT, WITH COUNSEL OF THEIR CHOICE, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT ANY OF THEM MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY RELATED INSTRUMENT OR LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTION OF ANY OF THEM. THESE PROVISIONS SHALL NOT BE DEEMED TO HAVE BEEN MODIFIED IN ANY RESPECT OR RELINQUISHED BY BANK OR BORROWER, EXCEPT BY A WRITTEN INSTRUMENT EXECUTED BY EACH OF THEM. If the jury waiver set forth in this Section 11 is not enforceable, then any dispute, controversy, claim, action or similar proceeding arising out of or relating to this Agreement, the Loan Documents or any of the transactions contemplated therein shall be settled by final and binding arbitration held in San Mateo County, California in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with those rules. The arbitrator shall apply California law to the resolution of any dispute, without reference to rules of conflicts of law or rules of statutory arbitration. Judgment upon any award resulting from arbitration may be entered into and enforced by any state or federal court having jurisdiction thereof. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this Section. The costs and expenses of the arbitration, including without limitation, the arbitrator’s fees and expert witness fees, and reasonable attorneys’ fees, incurred by the parties to the arbitration may be awarded to the prevailing party, in the discretion of the arbitrator, or may be apportioned between the parties in any manner deemed appropriate by the arbitrator. Unless and until the arbitrator decides that one party is to pay for all (or a share) of such costs and expenses, both parties shall share equally in the payment of the arbitrator’s fees as and when billed by the arbitrator.

 

12.      GENERAL PROVISIONS .

 

12.1     Successors and Assigns . This Agreement shall bind and inure to the benefit of the respective successors and permitted assigns of each of the parties and shall bind all persons who become bound as a debtor to this Agreement; provided, however, that neither this Agreement nor any rights hereunder may be assigned by Borrower without Bank’s prior written consent, which consent may be granted or withheld in Bank’s sole discretion. Bank shall have the right without the consent of or notice to Borrower to sell, assign, transfer, negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations, rights and benefits hereunder.

 

12.2     Indemnification . Borrower shall defend, indemnify and hold harmless Bank and its officers, employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Agreement; and (b) all losses or Bank Expenses in any way suffered, incurred, or paid by Bank, its officers, employees and agents as a result of or in any way arising out of, following, or consequential to transactions between Bank and Borrower whether under this Agreement, or otherwise (including without limitation reasonable attorneys fees and expenses), except for losses caused by Bank’s gross negligence or willful misconduct.

 

 
16.

 

 

12.3     Time of Essence . Time is of the essence for the performance of all obligations set forth in this Agreement.

 

12.4     Severability of Provisions . Each provision of this Agreement shall be severable from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision.

 

12.5     Amendments in Writing, Integration. All amendments to or terminations of this Agreement or the other Loan Documents must be in writing and executed by Borrower and Bank. All prior agreements, understandings, representations, warranties, and negotiations between the parties hereto with respect to the subject matter of this Agreement and the other Loan Documents, if any, are merged into this Agreement and the Loan Documents.

 

12.6     Counterparts . This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement. Executed copies of the signature pages of this Agreement sent by facsimile or transmitted electronically in Portable Document Format (“PDF”), or any similar format, shall be treated as originals, fully binding and with full legal force and effect, and the parties waive any rights they may have to object to such treatment.

 

12.7     Survival . All covenants, representations and warranties made in this Agreement shall continue in full force and effect so long as any Obligations remain outstanding or Bank has any obligation to make any Credit Extension to Borrower. The obligations of Borrower to indemnify Bank with respect to the expenses, damages, losses, costs and liabilities described in Section 12.2 shall survive until all applicable statute of limitations periods with respect to actions that may be brought against Bank have run.

 

12.8     Confidentiality . In handling any confidential information, Bank and Borrower and all employees and agents of each such party shall exercise the same degree of care that such party exercises with respect to its own proprietary information of the same types to maintain the confidentiality of any non-public information thereby received or received pursuant to this Agreement except that disclosure of such information may be made (i) in the case of Bank, to the subsidiaries or Affiliates of Bank or Borrower in connection with their present or prospective business relations with Borrower, (ii) in the case of Bank, to prospective transferees or purchasers of any interest in the Credit Extensions, provided that they have entered into a comparable confidentiality agreement in favor of Borrower and have delivered a copy to Borrower, (iii) as required by law, regulations, rule or order, subpoena, judicial order or similar order, (iv) in the case of Bank, as may be required in connection with the examination, audit or similar investigation of Bank and (v) as Bank may determine in connection with the enforcement of any remedies hereunder. Confidential information hereunder shall not include information that either: (a) is in the public domain or in the knowledge or possession of the receiving party when disclosed to such party, or becomes part of the public domain after disclosure to such receiving party through no fault of such receiving party; or (b) is disclosed to such receiving party by a third party, provided the receiving party does not have actual knowledge that such third party is prohibited from disclosing such information. Bank acknowledges and agrees that Parent may be required to report or otherwise disclose the entry into this Agreement, and file this Agreement and any exhibits and schedules hereto as exhibits to any such reports or disclosure documents, pursuant to the requirements of the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, and that this Agreement and its exhibits and schedules would not constitute confidential information hereunder in such event.

 

[SIGNATURE PAGE FOLLOWS.]

 

 
17.

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first above written.

 

 

 

VIVEVE, INC.

 
       
       
 

By:

/s/Scott Durbin

 
       
 

Name:

Scott Durbin

 
       
 

Title:

CFO

 
       
       
 

SQUARE 1 BANK

 
       
       
 

By:

/s/Ben Colombo

 
       
 

Name:

 Ben Colombo

 
       
 

Title:

 Sr. Vice President

 

 

 
1. 

 

 

EXHIBIT A

 

DEFINITIONS

 

“Accounts” means all presently existing and hereafter arising accounts, contract rights, payment intangibles and all other forms of obligations owing to Borrower arising out of the sale or lease of goods (including, without limitation, the licensing of software and other technology) or the rendering of services by Borrower and any and all credit insurance, guaranties, and other security therefor, as well as all merchandise returned to or reclaimed by Borrower and Borrower’s Books relating to any of the foregoing.

 

“Affiliate” means, with respect to any Person, any Person that owns or controls directly or indirectly such Person, any Person that controls or is controlled by or is under common control with such Person, and each of such Person’s senior executive officers, directors, and general partners.

 

“Applicable Margin” means 4.0% as to Tranche 1 Term Advances and Tranche 2 Term Advances; and 5.5% as to Tranche 3 Term Advances.

 

“Authorized Officer” means someone designated as such in the corporate resolution provided by Borrower to Bank in which this Agreement and the transactions contemplated hereunder are authorized by Borrower’s board of directors. If Borrower provides subsequent corporate resolutions to Bank after the Closing Date, the individual(s) designated as “Authorized Officer(s)” in the most-recently provided resolution shall be the only “Authorized Officers” for purposes of this Agreement.

 

“Bank Expenses” means all reasonable costs or expenses (including reasonable attorneys’ fees and expenses, whether generated in-house or by outside counsel) incurred in connection with the preparation, negotiation, administration, and enforcement of the Loan Documents; reasonable Collateral audit fees; and Bank’s reasonable attorneys’ fees and expenses (whether generated in-house or by outside counsel) incurred in amending, enforcing or defending the Loan Documents (including fees and expenses of appeal), incurred before, during and after an Insolvency Proceeding, whether or not suit is brought.

 

“Basic Rate” is the per annum rate of interest (based on a year of 360 days) equal to the U.S. Treasury note yield to maturity for a term equal to 36 months as reported in the Federal Reserve Statistical Release H.15-Selected Interest Rates under the heading “U.S. Government Securities/Treasury Constant Maturities” on the Funding Date. (In the event Release H.15 is no longer published, Bank shall select a comparable publication to determine the U.S. Treasury note yield to maturity.)

 

“Borrower’s Books” means all of Borrower’s books and records including: ledgers; records concerning Borrower’s assets or liabilities, the Collateral, business operations or financial condition; and all computer programs, or tape files, and the equipment, containing such information.

 

“Business Day” means any day that is not a Saturday, Sunday, or other day on which banks in the State of North Carolina are authorized or required to close.

 

“Cash” means unrestricted cash and cash equivalents.

 

“Change in Control” shall mean a transaction other than a bona fide equity financing or series of financings on terms and from investors reasonably acceptable to Bank in which any “person” or “group” (within the meaning of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of Borrower ordinarily entitled to vote in the election of directors, empowering such “person” or “group” to elect a majority of the Board of Directors of Borrower, who did not have such power before such transaction.

 

“Closing Date” means the date of this Agreement.

 

 
1.

 

 

“Code” means the Uniform Commercial Code as amended or supplemented from time to time.

 

“Collateral” means the property described on Exhibit B attached hereto and all Negotiable Collateral to the extent not described on Exhibit B, except to the extent any such property (i) is nonassignable by its terms without the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, §9406 and §9408 of the Code), (ii) the granting of a security interest therein is contrary to applicable law, provided that upon the cessation of any such restriction or prohibition, such property shall automatically become part of the Collateral, (iii) constitutes the capital stock of a controlled foreign corporation (as defined in the IRC), in excess of 65% of the voting power of all classes of capital stock of such controlled foreign corporations entitled to vote, or (iv) property (including any attachments, accessions or replacements) that is subject to a Lien that is permitted pursuant to clause (c) of the definition of Permitted Liens, if the grant of a security interest with respect to such property pursuant to this Agreement would be prohibited by the agreement creating such Permitted Lien or would otherwise constitute a default thereunder, provided, that such property will be deemed "Collateral" hereunder upon the termination and release of such Permitted Lien.

 

“Collateral State” means the state or states where the Collateral is located, which is California.

 

“Compliance Certificate” means a compliance certificate, in substantially the form of Exhibit E attached hereto, executed by a Responsible Officer of the Borrower.

 

“Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including, without limitation, any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.

 

“Copyrights” means any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held.

 

“Credit Extension” means each Term Loan or any other extension of credit by Bank, to or for the benefit of Borrower hereunder.

 

“Equipment” means all present and future machinery, equipment, tenant improvements, furniture, fixtures, vehicles, tools, parts and attachments in which Borrower has any interest.

 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations thereunder.

 

“Event of Default” has the meaning assigned in Article 8.

 

“Final Payment” means a payment (i) with respect to Tranche and Tranche 2, an amount equal to 6.8% of the aggregate original principal amount of the Tranche 1 Term Advances and Tranche 2 Term Advances, respectively and (ii) with respect to Tranche 3, an amount equal to 3.5% of the aggregate original principal amount of the Tranche 3 Term Advances.

 

 
2.

 

 

“GAAP” means generally accepted accounting principles, consistently applied, as in effect from time to time in the United States.

 

“Guaranty” means the guaranty by Parent of even date for the benefit of Bank.

 

“Indebtedness” means (a) all indebtedness for borrowed money or the deferred purchase price of property or services, including without limitation reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations, including but not limited to any sublimit contained herein.

 

“Insolvency Proceeding” means any proceeding commenced by or against any Person or entity under any provision of the United States Bankruptcy Code, as amended, or under any other bankruptcy or insolvency law, including assignments for the benefit of creditors, formal or informal moratoria, compositions, extension generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.

 

“Intellectual Property Collateral” means all of Borrower’s right, title, and interest in and to the following:

 

(a)      Copyrights, Trademarks and Patents;

 

(b)      Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

 

(c)      Any and all design rights which may be available to Borrower now or hereafter existing, created, acquired or held;

 

(d)      Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

 

(e)      All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

 

(f)      All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

 

(g)      All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

 

“Inventory” means all present and future inventory in which Borrower has any interest.

 

“Investment” means any beneficial ownership of (including stock, partnership or limited liability company interest or other securities) any Person, or any loan, advance or capital contribution to any Person.

 

“Investment Agreement” means , collectively, Borrower’s stock purchase and other agreement(s) pursuant to which Borrower most recently issued its preferred stock .

 

“IRC” means the Internal Revenue Code of 1986, as amended, and the regulations thereunder.

 

“Lien” means any mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance.

 

“Loan Documents” means, collectively, this Agreement, any note or notes executed by Borrower, and any other document, instrument or agreement entered into in connection with this Agreement, all as amended or extended from time to time.

 

“Material Adverse Effect” means a material adverse effect on (i) the operations, business or financial condition of Borrower and its Subsidiaries taken as a whole, (ii) the ability of Borrower to repay the Obligations or otherwise perform its obligations under the Loan Documents, or (iii) Borrower’s interest in, or the value, perfection or priority of Bank’s security interest in the Collateral.

 

 
3.

 

 

“Merger” is the merger consummated pursuant to the Agreement and Plan of Merger by and among Viveve, Inc., PLC Systems, Inc. and PLC Systems Acquisition Corporation dated as of May 9, 2014.

 

“Negotiable Collateral” means all of Borrower’s present and future letters of credit of which it is a beneficiary, drafts, instruments (including promissory notes), securities, documents of title, and chattel paper, and Borrower’s Books relating to any of the foregoing.

 

“New Equity” means cash proceeds received from the sale or issuance of Parent’s equity or Subordinated Debt securities.

 

“Obligations” means all debt, principal, interest, Bank Expenses and other amounts owed to Bank by Borrower pursuant to this Agreement or any other agreement, whether absolute or contingent, due or to become due, now existing or hereafter arising, including any interest that accrues after the commencement of an Insolvency Proceeding and including any debt, liability, or obligation owing from Borrower to others that Bank may have obtained by assignment or otherwise.

 

“OUS Clinical Trial” means the VIVEVE I Clinical Study - Viveve Treatment of the Vaginal Introitus to Evaluate Efficacy - being conducted in Europe and Canada.

 

“Parent” means Viveve Medical, Inc. (formerly, PLC Systems, Inc.), a Yukon Territory corporation, of which Borrower is a wholly-owned subsidiary.

 

“Patents” means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same.

 

“Periodic Payments” means all installments or similar recurring payments that Borrower may now or hereafter become obligated to pay to Bank pursuant to the terms and provisions of any instrument, or agreement now or hereafter in existence between Borrower and Bank.

 

“Permitted Indebtedness” means:

 

(a)      Indebtedness of Borrower in favor of Bank arising under this Agreement or any other Loan Document;

 

(b)      Indebtedness existing on the Closing Date and disclosed in the Schedule;

 

(c)      Indebtedness not to exceed $100,000 in the aggregate at any time secured by a lien described in clause (c) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed at the time it is incurred the lesser of the cost or fair market value of the property financed with such Indebtedness;

 

(d)      Subordinated Debt;

 

(e)      Indebtedness to trade creditors incurred in the ordinary course of business; and

 

(f)      Extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be.

 

“Permitted Investment” means:

 

(a)      Investments existing on the Closing Date disclosed in the Schedule;

 

(b)      (i) Marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof, (ii) commercial paper maturing no more than one year from the date of creation thereof and currently having rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (iii) Bank’s certificates of deposit maturing no more than one year from the date of investment therein, and (iv) Bank’s money market accounts; (v) Investments in regular deposit or checking accounts held with Bank or as otherwise permitted by, and subject to the terms and conditions of, Section 6.6 of this Agreement; and (vi) Investments consistent with any investment policy adopted by the Borrower’s board of directors;

 

 
4.

 

 

(c)      Investments accepted in connection with Permitted Transfers;

 

(d)      Investments of Subsidiaries in or to other Subsidiaries or Borrower and Investments by Borrower in Subsidiaries not to exceed $100,000 in the aggregate in any fiscal year;

 

(e)      Investments not to exceed $100,000 outstanding in the aggregate at any time consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plan agreements approved by Borrower’s Board of Directors;

 

(f)      Investments in unfinanced capital expenditures in any fiscal year, not to exceed $100,000;

 

(g)      Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business;

 

(h)      Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (h) shall not apply to Investments of Borrower in any Subsidiary;

 

(i)      Joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the non-exclusive licensing of technology, the development of technology or the providing of technical support, provided that any cash Investments by Borrower do not exceed $100,000 in the aggregate in any fiscal year; and

 

(j)      Investments permitted under Section 7.3.

 

“Permitted Liens” means the following:

 

(a)      Any Liens existing on the Closing Date and disclosed in the Schedule (excluding Liens to be satisfied with the proceeds of the Credit Extensions) or arising under this Agreement, the other Loan Documents, or any other agreement in favor of Bank;

 

(b)      Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings and for which Borrower maintains adequate reserves;

 

(c)      Liens not to exceed $100,000 in the aggregate at any time (i) upon or in any Equipment (other than Equipment financed by a Credit Extension) acquired or held by Borrower or any of its Subsidiaries to secure the purchase price of such Equipment or indebtedness incurred solely for the purpose of financing the acquisition or lease of such Equipment, or (ii) existing on such Equipment at the time of its acquisition, in each case provided that the Lien is confined solely to the property so acquired and improvements thereon, and the proceeds of such Equipment;

 

(d)      Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (a) through (c) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced does not increase;

 

 
5.

 

 

(e)      Liens securing Subordinated Debt; and

 

(f)      Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Sections 8.4 (attachment) or 8.7 (judgments);

 

“Permitted Transfer” means the conveyance, sale, lease, transfer or disposition by Borrower or any Subsidiary of:

 

(a)      Inventory in the ordinary course of business;

 

(b)      licenses and similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary course of business;

 

(c)      worn-out, surplus or obsolete Equipment not financed with the proceeds of Credit Extensions unless Borrower receives the written consent of Bank;

 

(d)      grants of security interests and other Liens that constitute Permitted Liens; and

 

(e)      other assets of Borrower or its Subsidiaries that do not in the aggregate exceed $[250,000] during any fiscal year.

 

“Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or governmental agency.

 

“Prime Rate” means the variable rate of interest, per annum, most recently announced by Bank, as its “prime rate,” whether or not such announced rate is the lowest rate available from Bank.

 

“Responsible Officer” means each of the Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer, Vice President of Finance and the Controller of Borrower, as well as any other officer or employee identified as an Authorized Officer in the corporate resolution delivered by Borrower to Bank in connection with this Agreement.

 

“Revenue” means revenue recognized in accordance with GAAP.

 

“Schedule” means the schedule of exceptions attached hereto and approved by Bank, if any.

 

“SOS Reports” means the official reports from the Secretaries of State of each Collateral State, the state where Borrower’s chief executive office is located, the state of Borrower’s formation and other applicable federal, state or local government offices identifying all current security interests filed in the Collateral and Liens of record as of the date of such report.

 

“Subordinated Debt” means any debt incurred by Borrower that is subordinated in writing to the debt owing by Borrower to Bank on terms reasonably acceptable to Bank (and identified as being such by Borrower and Bank).

 

“Subsidiary” means any corporation, partnership or limited liability company or joint venture in which (i) any general partnership interest or (ii) more than 50% of the stock, limited liability company interest or joint venture of which by the terms thereof ordinary voting power to elect the Board of Directors, managers or trustees of the entity, at the time as of which any determination is being made, is owned by Borrower, either directly or through an Affiliate.

 

“Term Loan” or “Term Loans” are cash advances made under Section 2.1.

 

“Term Loan Maturity Date” means, as to each Term Loan, the date that is 42 months after the date of such Term Loan.

 

 
6.

 

 

“Trademarks” means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.

 

“Tranche” means any of Tranche 1, Tranche 2, or Tranche 3.

 

“Tranche 1” has the meaning assigned in Section 2.1(i).

 

“Tranche 1 Term Advance” means the Term Loan made under Tranche 1.

 

“Tranche 2” has the meaning assigned in Section 2.1(i).

 

“Tranche 2 Term Advance” or “Tranche 2 Term Advances” means the Term Loan or Term Loans made under Tranche 2.

 

“Tranche 3” has the meaning assigned in Section 2.1(i).

 

“Tranche 3 Term Advance” or “Tranche 3 Term Advances” means the Term Loan or Term Loans made under Tranche 3.

 

 
7.

 

 

DEBTOR

VIVEVE, INC.

 

SECURED PARTY:

SQUARE 1 BANK

 

EXHIBIT B

 

COLLATERAL DESCRIPTION ATTACHMENT TO LOAN AND SECURITY AGREEMENT

 

All personal property of Borrower (herein referred to as “Borrower” or “Debtor”) whether presently existing or hereafter created or acquired, and wherever located, including, but not limited to:

 

(a)      all accounts (including health-care-insurance receivables), chattel paper (including tangible and electronic chattel paper), deposit accounts, documents (including negotiable documents), equipment (including all accessions and additions thereto), financial assets, general intangibles (including patents, trademarks, copyrights, goodwill, payment intangibles, domain names and software), goods (including fixtures), instruments (including promissory notes), inventory (including all goods held for sale or lease or to be furnished under a contract of service, and including returns and repossessions), investment property (including securities and securities entitlements), letter of credit rights, money, and all of Debtor’s books and records with respect to any of the foregoing, and the computers and equipment containing said books and records;

 

(b)      any and all cash proceeds and/or noncash proceeds of any of the foregoing, including, without limitation, insurance proceeds, and all supporting obligations and the security therefor or for any right to payment. All terms above have the meanings given to them in the California Uniform Commercial Code, as amended or supplemented from time to time, including revised Division 9 of the Uniform Commercial Code-Secured Transactions.

 

 
 

 

 

EXHIBIT C

 

LOAN ADVANCE / PAYDOWN REQUEST FORM

 

[Please refer to New Borrower Kit]

 

 

EXHIBIT D

 

COMPLIANCE CERTIFICATE

 

[Please refer to New Borrower Kit]

 

 
 

 

 

SCHEDULE OF EXCEPTIONS

 

 

PERMITTED INDEBTEDNESS

 

 

Indebtedness to trade creditors incurred in the ordinary course of business totaling $201,869 on September 26, 2014.

 

 

PERMITTED INVESTMENTS

 

 

None

 

 

PERMITTED LIENS

 

 

None

SCHEDULE 5.3

 

 

COLLATERAL

 

 

Until repayment in full of the loan provided to the Company pursuant to that certain Loan and Security Agreement dated as of April 19, 2012 among Oxford Finance LLC, as collateral agent for various lenders (the “Lenders”), and the Company, the Collateral will be subject to a lien in favor of the Lenders.

 

 
 

 

 

SCHEDULE 5.4

 

INTELLECTUAL PROPERTY SCHEDULE

 

Summary of Patent Applications being managed by ShayGlenn LLP

 

Our file

Title

Application No.

Filing Date

National phase date

Publication No.

Publication Date

Patent No.

Issue Date

Status

10095-701.101

VAGINAL REJUVENATION TREATMENT DEVICE AND METHODS

60/743,247

February 7, 2006

         

Closed

10095-701.201

VAGINAL REMODELING DEVICE AND METHODS

11/704,067

February 7, 2007

 

US-2007-0233191-A1

October 4, 2007

   

Published

10095-701.601

VAGINAL REMODELING DEVICE AND METHODS

PCT/US2007/003542

February 7, 2007

 

WO 2007/092610

August 16, 2007

   

Closed

10095-702.100

VAGINAL REMODELING DEVICE AND METHODS

61/243,686

September 18, 2009

         

Closed

10095-702.200

VAGINAL REMODELING DEVICE AND METHODS

12/884,108

September 16, 2010

 

US-2011-0178584-A1

July 21, 2011

   

Published

10095-702.600

VAGINAL REMODELING DEVICE AND METHODS

PCT/US2010/049045

September 16, 2010

 

WO 2011/034986

March 24, 2011

   

Closed

10095-702.AU0

VAGINAL REMODELING DEVICE AND METHODS

2010295586

September 16, 2010

March 20, 2012

       

Pending

10095-702.BR0

VAGINAL REMODELING DEVICE AND METHODS

BR 11 2012 006059 7

September 16, 2010

March 16, 2012

       

Pending

10095-702.CA0

VAGINAL REMODELING DEVICE AND METHODS

2,774,265

September 16, 2010

March 14, 2012

       

Pending

10095-702.CN0

VAGINAL REMODELING DEVICE AND METHODS

 

September 16, 2010

         

Unfiled

10095-702.EP0

VAGINAL REMODELING DEVICE AND METHODS

10817805.4

September 16, 2010

March 30, 2012

2477695

July 25, 2012

   

Published

10095-702.HK0

VAGINAL REMODELING DEVICE AND METHODS

10817805.4

September 16, 2010

August 22, 2012

2477695

July 25, 2012

   

Published

10095-702.IN0

VAGINAL REMODELING DEVICE AND METHODS

2321/DELNP/2012

September 16, 2010

March 16, 2012

       

Pending

10095-702.JP0

VAGINAL REMODELING DEVICE AND METHODS

2012-529890

September 16, 2010

March 16, 2012

2013-505069

February 14, 2013

   

Published

10095-702.KR0

VAGINAL REMODELING DEVICE AND METHODS

10-2012-7009840

September 16, 2010

April 17, 2012

10-2012-0100921

September 12, 2012

   

Published

10095-702.TW0

VAGINAL REMODELING DEVICE AND METHODS

099133093

September 29, 2010

 

201212879

April 1, 2012

   

Published

 

 

 

 

616     

DOCKET SUMMARY from Law Offices of Albert Wai-Kit Chan, PLLC

 

OUR

DOCKET

SUBJECT MATTER

DEADLINES / STATUS

1595

General Matters

September 9, 2011: Slides and other information sent by client.

September 12, 2011 : Conference call.

September 13, 2011: File histories sent by Jim Shay.

September 22, 2011 : Conference call. S. Lopez sent clarification of changes between generations 1 and 2 of invention.

September 29, 2011 : Conference call.

October 2, 2011: Conference call.

November 28, 2011: Conference call.

December 2, 2011: Portfolio Status sent.

December 13, 2011: Portfolio Status and filing strategy sent.

December 16, 2011: Conference call regarding overall filing strategy.

March 13, 2012: Meeting with client at Viveve.

December 20, 2012: Conference call regarding Hong Kong Short-term patent applications.

February 20, 2013 : Teleconference with P. Scheller on PCT, US and TW filings.

March 7, 2013 : Teleconference with P. Scheller on assignments and filing strategy.

April 09, 2013 : Teleconference with P. Scheller and S. Durbin on assignments and IP procurement.

December 19 , 2013 : Sent Patent Log per client ’s request.

January 10, 2014 : Teleconference with P. Scheller.

April 2, 2014 : Sent Patent Log per client ’s request.

July 10, 2014 : Teleconference with P. Scheller on national stage filings for 1614-A-PCT.

     
 

Docket Summary &

Action List

July 14, 2014: Last   Docket summary sent.

September 22, 2014 : Current Docket Summary.

     

1595-A

Company name (in Chinese)

and related issues

March 15, 2012: Client decided on Chinese name (女康乐公司 ).

     

1595-B

Ownership/Assignment/

Agreement

March 29, 2012 : Draft assignments sent to client for execution.

April 19, 2012 : Followed up with client regarding execution of assignments.

April 23, 2012 : Client placed hold on docket.

January 22, 2013 : Client sent executed assignments (D. Galen to Viveve and Viveve employees to Viveve).

March 04, 2013 : Client sent executed assignments (Stellartech to Viveve and Stellartech employeess to Stellartech). Assignment from Stellartech to Viveve did not contain the verbiage as proposed.

March 06, 2013 : Raised assignment issues for client to follow up.

March 07, 2013 : Client sent documents and agreements related to Dr. J. Parmer; Teleconference with client on assignments.

 

 
 

 

 

   

March 12, 2013 : Asked client to address two assignment issues.

March 13, 2013 : Client sent executed assignment (Stellartech to Viveve) containing the verbiage as proposed.

April 11, 2013 : Sent draft assignment (J. Parmer to Viveve) to client.

October 08, 2013 : Client informed that it would be difficult to obtain assignment from Dr. Parmer.

March 31, 2014 : Client asked for assistance in evaluating a merger agreement with regard to intellectual property.

     

1609

Intellectual Property Agreement with a Chinese partner

November 27, 2011: Received instructions from client to draft agreement re status of partner (Donna Bella) in China to defend IP.  

November 28, 2011: Draft sent to client.

December 1, 2011: Updated draft sent to client; Client needed nothing more.

J uly 08, 2013: Client requested to send the draft agreement; Sent draft to client.

J uly 12, 2013: Client indicated the previous draft agreement has not been sent to Donna Bella.

     

1625-TM-CN

Chinese Trademark Application for 女康 , Application No. 10892459 for International Class 10; Application No. 10892458 for International Class 41; Application No. 10892457 for International Class 44, All Filed May 10, 2012

STATUS: REGISTERED

 

August 14, 2013: Trademark registered.

October 18, 2013 : Sent Certificate to client.

August 13, 2023: Trademark expires.

 

DEADLINE :

February 13, 2023 - February 13, 2024: File renewal for   Trademark.

1601-0-(US)

VAGINAL REMODELING DEVICE AND METHODS, U.S. Serial No. 1 1/ 704,0 67, Filed February  07, 2007, which claims benefit of U.S. Serial No. 60/743,247, Filed February  07, 2006

STATUS: PENDING ( Prosecuted by client)

 

February 07, 2007 : Application filed.

October 04, 2007 : Application published as US20070233191A1.

April 15, 2011 : Request for Continued Examination filed.

February 13, 2014 : Office Action issued.

June 09, 2014 : Response filed.

August 08, 2014 : Office Action issued.

[OA indicates there are allowable subject matters (method)]

 

DEADLINES:

November 08, 2014 : File Response to Office Action

February 08, 2015 (abs) : File Response to Office Action

     

 

 
 

 

 

1601-(US)

VAGINAL REMODELING DEVICE AND METHODS, U.S. Serial No. 12/884,108 ,

Filed September 16 , 2010, which claims benefit of U.S. Serial No. 61/243,686, Filed September 18, 2009

Inventors:  

Jonathan B. PARMER , Ian F. SMITH , Chun-Chih CHENG , Patrick Karl HOWE , Sean Yasuo SULLIVAN , Jerome JACKSON , Stanley LEVY , Jr., Sherree Leigh LUCAS , Steven Marc LOPEZ

STATUS: PENDING ( Prosecuted by client)

 

September 16, 2010 : Application filed.

July 21, 2011 : Application published as US20110178584A1.

February 6, 2014 : final Office Action issued.

June 6, 2014 : Response filed.

June 26, 2014 : Advisory Action issued.

August 05, 2014 : Response and Request for Continued Examination filed.

August 27, 2014 : Office Action issued.

DEADLINES:

November 27, 2014 : File Response to Office Action

February 27, 2015 (abs) : File Response to Office Action

     

1601-(PCT)

VAGINAL REMODELING DEVICE AND METHODS , International Application No. PCT/US2010/049045, Filed September 16, 2010, which claims benefit of U.S. Serial No. 61/243,686, Filed September 18, 2009

Inventors:  

Jonathan B. PARMER , Ian F. SMITH , Chun-Chih CHENG , Patrick Karl HOWE , Sean Yasuo SULLIVAN , Jerome JACKSON , Stanley LEVY , Jr., Sherree Leigh LUCAS , Steven Marc LOPEZ

STATUS: EXPIRED

 

September 16, 2010 : Application filed.

March 24, 2011 : Application published as WO2011/034986.

     

1601-PCT-(AU)

VAGINAL REMODELING DEVICE AND METHODS , Australian Application No. 2010295586, filed March 20, 2012, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

March 20, 2012 : National application filed.

April 12, 2012 : Application published as AU2010295586.

     

1601-PCT-(BR)

VAGINAL REMODELING DEVICE AND METHODS , Brazilian Application No. BR11 2012 006059 7, filed September 16, 2010, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

     

1601-PCT-(CA)

VAGINAL REMODELING DEVICE AND METHODS , Canadian Application No. 2,774,265, filed March 14, 2012, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

March 14, 2012 : National application filed.

 

*Application published as CA2774265.

     

 

 
 

 

 

1601-PCT-CN

VAGINAL REMODELING DEVICE AND METHODS ( 修改阴道组织的仪器和方法 ) , Chinese Application No. 201080049557.4, Filed May 18, 2012, National stage of International Application No. PCT/US2010/049045

STATUS: PENDING

 

March 1 6 , 2012:  English application filed.

March 21, 2012: Reported filing of English application.

May 02, 2012: Chinese application filed.

May 18, 2012: Reported filing of Chinese application.

May 24, 2012: Copy of filed Request for Examination sent to client.

October 15, 2012: Notice of International Applications Entering the National Phase issued.

October 16, 2012: Notice reported to client.

March 1 3 , 201 3 :  Application published as CN102971047A.

March 20, 201 3 : Notice of Publication and Entry into Substantive Examination issued.

October 08, 2013 : Client informed that it would be difficult to obtain assignment from Dr. Parmer.

April 08, 2014:  Request for  updating applicant ’s address filed and reported to client.

April 22, 2014: Notice of Granting Request for Changing Applicant's Address issued; reported to client.

 

Potential assignment issue with J. Parmer

Waiting for Office Action

     

1601-PCT-(EP)

VAGINAL REMODELING DEVICE AND METHODS , European Application No. 2010817805, filed March 30, 2012, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

March 30, 2012 : National application filed.

July 25, 2012 : Application published as EP2477695.

     

1601-PCT-EP-(HK)

VAGINAL REMODELING DEVICE AND METHODS , Hong Kong Standard Patent Application No. 12108243.4, Filed

August 22, 2012, corresponding to European Application No. 2010817805, filed March 30, 2012, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

August 22, 2012 : HK application filed.

December 07, 2012 : Application published as HK1167590.

     

1601-PCT-(IN)

VAGINAL REMODELING DEVICE AND METHODS , Indian Application No. 2321/DELNP/2012, filed September 16, 2010, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

     

1601-PCT-(JP)

VAGINAL REMODELING DEVICE AND METHODS , Japanese Application No. 2012-529890, filed March 16, 2012, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

March 16, 2012 : National application filed.

February 14, 2013 : Application published as JP2013-505069.

     

1601-PCT-(KR)

VAGINAL REMODELING DEVICE AND METHODS , Korean Application No. 10-2012-7009840, filed April 17, 2012, National Stage of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

April 17, 2012 : National application filed.

September 12, 2012 : Application published as KR10-2012-0100921.

     

 

 
 

 

 

1601-( TW )

VAGINAL REMODELING DEVICE AND METHODS, Taiwan Application No. 099133093, Filed September  29, 2010, which claim priority of International Application No. PCT/US2010/049045

STATUS: PENDING ( Prosecuted by client)

 

September   29, 2 0 10 : Application filed.

April 01, 2012 : Application published as TW201212879.

     

1602-CN-U

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ), Chinese Utility Model Application No. 201220099603.8, Filed March 16, 2012

Inventors:  

Jerome JACKSON ;

Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

December 27, 2012 : Notice of Grant issued.

April 10, 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity .

     

1602-HK

VAGINAL REMODELING DEVICE ( 一种 修复女性 阴道组织的治疗器 ), Hong Kong Short-term Patent App’l No. 13102976.9, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099603.8, filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued.

July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due.

     

1603-CN-U

VAGINAL REMODELING DEVICE WITH ELECTRODE FINGER HOLDER

( 一种具有电极手指套的修复女性阴道组织的治疗器 ) ,   Chinese Utility Model Application No. 201220099605.7, Filed March 16, 2012

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

January 08, 2013 : Notice of Grant issued.

April 10, 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

 

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity due.

     

 

 
 

 

 

1603-HK

VAGINAL REMODELING DEVICE WITH ELECTRODE FINGER HOLDER

( 一种具有电极手指套的修复女性阴道组织的治疗器 ) ,   Hong Kong Short-term Patent App’l No. 13102975.0, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099605.7, filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due.

     

1604-CN-U

VAGINAL REMODELING DEVICE WITH TEMPERATURE SENSOR ( 一种具有温度感应器的修复女性阴道组织的治疗器 ) ,   Chinese Utility Model Application No. 201220099618.4, Filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

 

October 17, 2012 : Notice of Grant issued.

December 28, 2012: Registration and Annuity Fees Paid.

February 13, 2012: Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity .

     

1604-HK

VAGINAL REMODELING DEVICE WITH TEMPERATURE SENSOR ( 一种具有温度感应器的修复女性阴道组织的治疗器 ) ,   Hong Kong Short-term Patent App’l No. 13102974.1, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099618.4, filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR

 

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

 

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due.

     

 

 
 

 

 

1607-CN-U

VAGINAL REMODELING DEVICE WITH DIRECTIONAL SENSORS( 一种裝有方向感应器的修复阴道组织的治疗器 ) ,   Chinese Utility Model Application No. 201220099620.1, Filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

 

October 31, 2012 : Notice of Grant issued.

February 27, 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity .

     

1607-HK

VAGINAL REMODELING DEVICE WITH DIRECTIONAL SENSORS( 一种裝有方向感应器的修复阴道组织的治疗器 ) ,   Hong Kong Short-term Patent App’l No. 13102973.2, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099620.1, filed March 16, 2012

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due.

1608-CN-U

VAGINAL REMODELING DEVICE AND SYSTEM WITH DEPTH MARKERS   ( 一种具有深度标记的修改阴道组织的仪器和系统 ) ,   Chinese Utility Model Application No. 201220099634.3, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

December 04, 2012 : Notice of Grant issued.

March 20, 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity due.

     

1608-HK

 

VAGINAL REMODELING DEVICE AND SYSTEM WITH DEPTH MARKERS   ( 一种具有深度标记的修改阴道组织的仪器和系统 ) ,   Hong Kong Short-term Patent App’l No. 13102972.3, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099634.3, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due.

     

 

 
 

 

 

1611-CN

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ) ,   Chinese Application No. 201210069908.9, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

December 16, 2011: Combining subject matters from 1602-CN and 1608-CN.

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client comments on figures.

March 15, 2012: Revised figures sent to client for approval.

March 20, 2012: Reported filing of application.

September 18, 2013: Application published.

September 25, 2013: Notice of Publication issued; Request for Examination filed.

October 08, 2013: Notice of Entry into Substantive Examination issued.

October 29, 2013: Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

October 31, 2013: Client instructed not to file amendment.

March 12, 2014: Client confirmed not to file HK standard application based on this application.

 

Waiting for Office Action

     

1612-CN

VAGINAL REMODELING DEVICE WITH TEMPERATURE SENSORS OR DEPTH MARKERS ( 一种具有温度感应器或深度标记的修复阴道组织的治疗器 ) ,   Chinese Application No. 201210069910.6, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

 

STATUS: PENDING

 

December 16, 2011: Combining subject matters from 1604-CN and 1608-CN.

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client approved.

March 20, 2012: Reported filing of application.

September 18, 2013: Application published.

September 25, 2013: Notice of Publication issued; Request for Examination filed.

September 30, 2013: Notice of Entry into Substantive Examination issued.

October 29, 2013: Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

November 04, 2013 : Voluntary Amendment on Specification and Claims filed.

November 05, 2013 : Reported filed Voluntary Amendment to client.

March 12, 2014: Client confirmed not to file HK standard application based on this application.  

September 04, 2014 : Office Action issued.

 

DEADLINES:

January 19, 2015 : File Response to Office Action

March 19, 2015 (abs) : File Response to Office Action

     

 

 
 

 

 

1613-CN

VAGINAL REMODELING DEVICE WITH DIRECTIONAL SENSORS OR DEPTH MARKERS ( 一种具有方向感应器或深度标记的修复阴道组织的治疗器 ) ,   Chinese Application No. 201210069909.3, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

December 16, 2011: Combining subject matters from 1607-CN and 1608-CN.

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client comments on figures.

March 15, 2012: Revised figures sent to client for approval.

March 20, 2012: Reported filing of application.

September 18, 2013: Application published.

September 25, 2013: Notice of Publication issued; Request for Examination filed.

October 09, 2013: Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

November 04, 2013 : Voluntary Amendment on Specification and Claims filed.

November 05, 2013 : Reported filed Voluntary Amendment to client.

March 12, 2014: Client confirmed not to file HK standard application based on this application.

August 26, 2014 : Office Action issued.

September 03, 2014 : Reported Office Action to client.

 

DEADLINES:

January 10, 2015 : File Response to Office Action

March 10, 2015 (absolute) : File Response to Office Action

     

1614-CN

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ) ,   Chinese   Application No. 201210069906.X, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

December 16, 2011: Combining subject matters from 1602-CN, 1603-CN, 1604-CN, 1607-CN and 1608-CN.

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client comments on figures.

March 15, 2012: Revised figures sent to client for approval.

March 21, 2012: Reported filing of application.

September 18, 2013: Application published.

September 25, 2013: Notice of Publication issued; Request for Examination filed.

September 30, 2013: Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

October 31, 2013: Client instructed not to file amendment.

March 12, 2014: Client instructed to file HK standard application based on this application.

September 04, 2014 : Office Action issued.

 

DEADLINES:

January 10, 2015 : File Response to Office Action

March 10, 2015 (absolute) : File Response to Office Action

     

 

 
 

 

 

1614-CN-HK

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ) ,   HK Application No. 14102600.2, filed March 15, 2014, corresponding to Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

March 12, 2014: Client instructed to file HK standard application based on 1614-CN.

March 15, 2014: Request to Record a Designated Patent (Stage 1 application) filed.

March 17, 2014: Reported to client on filed application.

April 25, 2014: Accorded Filing Date Notification Letter issued and reported to client.

May 16, 2014: Notification of Publication of the Request to Record issued

May 19, 2014: Reported Notification of Publication of the Request to Record.

June 13, 2014: Request to Record published.

June 17, 2014: Reported publication of Request to Record.

 

File Request for Registration and Grant (Stage 2 application) once the Chinese application is granted

     

1614-CN-U

VAGINAL REMODELING DEVICE ( 一种修复女性阴道 组织的治疗器 ) , Chinese   Utility Model Application No. 201220099648.5, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

December 24, 2012 : Notice of Grant issued.

April 10, 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

 

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity due.

     

1614-HK

 

VAGINAL REMODELING DEVICE ( 一种修复女性阴道 组织的治疗器 ) , Hong Kong Short-term Patent App’l No. 13102971.4, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099648.5, filed March 16, 2012

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENETD

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due.

     

 

 
 

 

 

1614-A-PCT

VAGINAL REMODELING DEVICE AND METHOD, International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

March 15, 2013: Application filed.

April 8, 2013: Client agreed to   postpone entry into Luxembourg until the EP case is allowed and to file application in UK, France, Germany and Italy.

April 11, 2013: Client sent prioritizations on countries for 1614 application: US, Europe, China, Hong Kong, Japan, Canada, Brazil, Mexico, Australia, India, South Korea, Singapore and Luxembourg.

April 12, 2013: Reported receipt of PCT Notifications of International Application Number and of the International Filing Date, Concerning Payment of Prescribed Fees, Receipt of Search Copy, and Invitation to Correct Defects in the International Application.

April 29, 2013: Priority document received by WIPO .

April 30, 2013 : Reported receipt of PCT Notification of Date of Receipt of Priority Document or of Priority Application Number; Client informed application is not entering China.

May 22, 2013 : Communication to Invitation to Correct Defects filed.

May 28, 2013 : Receipt of PCT Notices of Receipt of Record Copy and Priority Document.

June 06, 2013 : Receipt of PCT Notification of Transmittal of The International Search Report and The Written Opinion, International Search Report (ISR) and Written Opinion (WO).

June 15, 2013 : Client inquired about protection in Russia and considered to begin prosecution within the next few months.

August 02, 2013 : Client confirmed not filing Amendment under Article 19.

September 19, 2013 : Notification Concerning Availability of the Publication of the International Application issued; Application published.

October 14, 2013 : Client sent updated list of prioritized countries and request quotation and informed will make final decision by June 16, 2014.

October 17, 2013 : PCT First Notice issued.

October 22, 2013 : Reported issuance of PCT First Notice to client.

November 01, 2013 : Sent options and cost for filing application in Saudi Arabia; Client would give further instructions.

June 16, 2014 : Reminded client on national stage entry.

July 10, 2014 : Informal Comments to Written Opinion filed with WIPO; Reported filed Informal Comments to client; Discussed with client on national entry.

July 11, 2014 : PCT Communication issued acknowledging receipt of Informal Comments.

July 14, 2014 : Reported PCT Communication to client.

July 22, 2014 : Client confirmed entering Europe, Japan, Canada, Brazil, Mexico, India, South Korea and Singapore.

July 23, 2014 : Client considered entering Russia, Australian or New Zealand after the 31-month deadline in view of financial status.

August 28, 2014 : Informed client that Canadian entry can be extended to September 16, 2015 with fee, but Mexican entry cannot be extended.

August 29, 2014 : Client instructed to postpone Canadian entry to September 16, 2015.

September 11, 2014 : Client confirmed not to file any Australian or New Zealand applications.

 

DEADLINES:

PCT National or Regional Phase Entry   

October 16, 2014: 31 months after earliest priority date

 

Countries/Regions Considered (as of 10/14/2013):

Tier 1: US (1614-A-US), Europe, Japan, Canada, China/HK (1614-CN, 1614-CN-HK, 1614-CN-U, 1614-HK)

Tier 2: Brazil, Mexico, Australia, India, South Korea

Tier 3: Singapore, Taiwan (1614-A-TW), Russia, New Zealand, Saudi Arabia, UAE, Israel

Tier 4: All other markets

 

Per August 29, 2014 email, client may file Canadian application by September 16, 2015.

     

 

 
 

 

 

1614-A-PCT-BR

VAGINAL REMODELING DEVICE AND METHOD , Brazilian Application No. 1120140228663, filed September 16, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

September 16, 2014: Application filed in Portuguese.

 

DEADLINES:

November 15, 2014: File Power of Attorney (original not required).

 

March 15, 2016: File Request for Examination and Voluntary Amendment.

 

June 15, 2015: Annuity Due.

     

1614-A-PCT-CA

VAGINAL REMODELING DEVICE AND METHOD , Canadian National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

August 29, 2014 : Client instructed to postpone Canadian entry to September 16, 2015.

 

DEADLINES:

September 16, 2015: Absolute deadline to enter Canada (with late entry fee).

 

Need to remind client by June 16, 2015 on filing application.

     

1614-A-PCT-EP

VAGINAL REMODELING DEVICE AND METHOD , European Application No. XXX, filed XXX, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

July 22, 2014 : Client confirmed filing European application.

 

DEADLINES:

October 16, 2014: Absolute deadline to enter Europe.

     

 

 
 

 

 

1614-A-PCT-IN

VAGINAL REMODELING DEVICE AND METHOD , Indian Application No. XXX, filed XXX, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

July 22, 2014 : Client confirmed filing Indian application.

 

DEADLINES:

October 16, 2014: Absolute deadline to enter India.

     

1614-A-PCT-JP

VAGINAL REMODELING DEVICE AND METHOD , Japanese Application No. Not yet known, filed September 16, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

September 16, 2014: Application filed in English; Petition for a 2-month extension for Japanese translation filed; Reported filed application to client.

 

DEADLINES:

November 16, 2014: File Japanese translation of application.  

March 15, 2016: File Request for Examination and Voluntary Amendment.

 

File Power of Attorney (original required).

     

1614-A-PCT-KR

VAGINAL REMODELING DEVICE AND METHOD , Korean Application No. XXX, filed XXX, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

July 22, 2014 : Client confirmed filing Korean application.

 

DEADLINES:

October 16, 2014: Absolute deadline to enter Korea.

     

 

 
 

 

 

1614-A-PCT-MX

VAGINAL REMODELING DEVICE AND METHOD , Mexican Application No. MX/A/2014/011097, filed September 15, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

September 10, 2014: Client confirmed small entity status of Viveve.

September 15, 2014: Application filed in English.

 

 

DEADLINES:

November 16, 2014: File Spanish translation of application.  

 

Need to instruct FA by October 16, 2014 to translate application.

File Power of Attorney (original required).

     

1614-A-PCT-SG

VAGINAL REMODELING DEVICE AND METHOD , Singapore Application No. 11201405630T, filed September 11, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

September 11, 2014: Application filed.

September 19, 2014: Reported filed application to client.

 

DEADLINES:

March 16, 2015 (36-month): File Request for Examination .

March 16, 2015 (36-month): File Request for Combined Search and Examination .

September 16, 2016 (54-month): File Request for Supplementary Examination based on Prescribed Information. *

 

* File when there is any positive Search and Examination result, or a granted patent from any of the prescribed countries**. Must be filed before issuance of an Examination Report, if a Request for Examination or Request for Combined Search and Examination has been filed.

 

** Prescribed Countries are Australia, Canada, Europe, Japan, New Zealand, Republic of Korea, United Kingdom and United States of America.

     

 

 
 

 

 

1614-A-TW

VAGINAL REMODELING DEVICE AND METHOD, Taiwanese App’l No. 102109033, filed March 14, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

March 12, 2013: Client sent executed POA.

March 14, 2013: Application filed with English Specification and Figures.

March 18, 2013: Reported application filed.

March 27, 2013 : Sent revised Chinese Specification and Figures to Foreign Associate.

April 15, 2013 : Sent Priority document to Foreign Associate.

May 28, 2013 : Priority document and Chinese Specification and Figures filed.

May 30, 2013 : Reported filed Priority document, Chinese specification and Figure.

September 23, 2013 : Foreign Associate informed application will be published on October 01, 2013.

October 01, 2013: Application laid-open.

October 14, 2013: Request to correct inventor name filed.

October 15, 2013: Client wanted to add “and/or exhaust” into the specification.

October 22, 2013: Request to correct inventor name allowed.

October 28, 2013: Reported   Correction of inventor name to client.

October 31, 2013: Client would give instruction on filing Voluntary Amendment in early 2014.

 

DEADLINE:

March 14, 2016: Filing   Request for Substantive Examination and Voluntary Amendment.

     

1614-A-US

VAGINAL REMODELING DEVICE AND METHOD, U.S. Serial No. 13/835,748, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

 

 

 

STATUS: PENDING

 

March 11, 2013: Sent client draft and formal papers to be filed

March 12, 2013: Client sent executed POA.

March 14, 2013: Client sent executed Declaration from five inventors.

March 15, 2013: Application and Preliminary amendment filed.

March 18, 2013: Reported application filed.

March 20, 2013: Client sent IDS checklist and relevant materials.

March 29, 2013: Client sent Declaration from Dr. Galen.

May 17, 2013: Reported filed Response to Notice to File Corrected Application Papers and Declaration from Dr. Galen.

May 22, 2013: Reported receipt of Filing Receipt and Notice of Acceptance of Power of Attorney;

May 29, 2013: Reported receipt of updated Filing Receipt.

July 17, 2013 : IDS filed.

July 18, 2013 : Reported filing of IDS.

September 19, 2013 : Notice of Publication of Application issued; Application published as US 2013/0245728.

September 23, 2013 : Reported published application to client.

September 19, 2014 : Sent IDS to client for review.

 

Waiting for action from USPTO

 

 

 
 

 

 

Other Ideas

SELF-ALIGNING TIP

October 07, 2011: Client sent idea in e-mail.

November 29, 2011: S. Lopez Update – “Viveve will not pursue this invention filing. Per previous discussion with K. Pope, idea incorporating ratcheting tip clocking mechanism deemed too expensive to manufacture against COGS target.”

     
 

FLOATING HAND PIECE CABLE

October 07, 2011: Client sent idea in e-mail.

November 09, 2011: Not to be pursued.

     
 

VISUAL LOCATOR MARKING ON HAND PIECE

October 07, 2011: Client sent idea in e-mail.

November 29, 2011: S. Lopez Update – “Visual markers incorporated into disposable treatment tip instead of hand piece. Embodiments for depth markers already submitted by Viveve under docket number 1608-CN.”

     
 

TREATMENT TIP SOFTWARE

October 04, 2011: Client sent idea in e-mail.

November 29, 2011 : S. Lopez Update – “Viveve will not pursue this invention filing in China. Per previous discussion with K. Pope, idea is likely considered a method and cannot be patented in China. Also, idea would provide too much confidential detail on how Viveve’s software operates the Viveve tip.”

     
 

MANUFACTURING INSPECTION PROCESS TO CHECK TREATMENT TIP

October 04, 2011: Client sent idea in e-mail.

November 29, 2011 : S. Lopez Update – “Viveve will not pursue this invention filing in China. Per previous discussion with K. Pope, idea is a method and cannot be patented in China. Per K. Pope, may later elect to file method invention in the USA.”

     
 

DIRECTIONAL SENSOR TO CONTROL CRYOGEN FLOW

September 20, 2011: Client sent idea in e-mail.

November 29, 2011: S. Lopez Update – “Cryogen flow control using directional sensors already documented under summary submitted by Viveve for docket number 1607-CN.”

     
 

MULTIPLE ELECTRODE CIRCUITS

September 20, 2011: Client sent idea in e-mail.

November 29, 2011: S. Lopez Update – “Multiple electrode circuit embodiment already documented in distributed electrode design (conical, round, etc) under docket numbers 1602-CN and 1603-CN. Updated sketches for docket number 1603-CN due from Stellartech on 11-30-11.”

     

 

 
 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

SCHEDULE 5.5

 

NAME

 

The Company was incorporated under the name TiVaMed, Inc. on September 21, 2005 and used that name until October 14, 2009.

 

 

SCHEDULE 5.6

 

LITIGATION

 

None

 

 
 

 

 

SCHEDULE 5.12

 

INBOUND LICENSES

 

Intellectual Property Assignment and License Agreement dated February 10, 2006 between TiVaMed, Inc. and Edward Knowlton

 

Development and Manufacturing Agreement dated June 12, 2006 between TiVaMed, Inc. and Stellartech Research Corporation

 

 
 

 

 

SCHEDULE 6.7(a)

 

REVENUE

 

This schedule will be provided by July 31, 2015 in form acceptable to Bank.

 

 
 

 

 

CORPORATE RESOLUTION

 

The undersigned duly elected and qualified [Assistant] Secretary of VIVEVE, INC. (the “Company”) do hereby certify that the following is a true and correct copy of certain resolutions adopted by the Company’s Board of Directors in accordance with applicable law and the Company’s bylaws, and that such resolutions are now unmodified and in full force and effect:

 

BE IT RESOLVED , that:

 

1)

Any one (1) of the following, duly elected officers of the Company (each, an “Authorized Officer”) whose genuine original signature appears next to his or her name is authorized to act for, on behalf of, and in the name of the Company in connection with the resolutions below:

 

Title   Name   Authorized Signature
         
         
   

 

   

 

       
         
         
         
         

 

 

 

2)

Any Authorized Officer may:

 

 

a)

Borrow money from time to time from Square 1 Bank (the “Bank”), and may negotiate and procure loans, letters of credit, foreign exchange contracts and other financial accommodations from Bank, including without limitation, that certain Loan and Security Agreement dated as of September 30, 2014, and also to execute and deliver to Bank one or more renewals, extensions, or modifications thereof;

 

 

b)

Give security for any liabilities of the Company to Bank by grant, security interest, assignment, lien, deed of trust or mortgage upon any real or personal property, tangible or intangible of the Company;

 

 

c)

Purchase, sell, exchange, assign, endorse for transfer and/or deliver certificates and/or instruments representing stocks, bonds, evidences of Indebtedness or other securities owned by the Company, whether or not registered in the name of the Company;

 

 

d)

Discount with the Bank, commercial or other business paper belonging to the Company made or drawn by or upon third parties, without limit as to amount;

 

 

e)

Authorize and direct the Bank to pay the proceeds of any such loans or discounts as directed by the persons so authorized to sign;

 

 

f)

Issue a warrant or warrants to purchase the Company’s capital stock;

 

 

g)

Execute and deliver in form and content as may be required by the Bank any and all notes, evidences of indebtedness, applications for letters of credit, guaranties, subordination agreements, loan and security agreements, financing statements, assignments, liens, deeds of trust, mortgages, trust receipts and other agreements, instruments or documents to carry out the purposes of these Resolutions, any or all of which may relate to all or to substantially all of the Company’s property and assets;

 

3)

The Authorized Officers may designate additional or alternate individuals as being authorized to request loan advances, to do and perform such other acts and things, to pay any and all fees and costs, and to execute and deliver such other documents and agreements as he or she may in his or her discretion deem reasonably necessary or proper in order to carry into effect the provisions of these Resolutions.

 

 
 

 

 

4)

Any and all acts authorized pursuant to these resolutions and performed prior to the passage of these resolutions are hereby ratified and approved, and the authority conferred herein may be exercised singly by any such officer, and these resolutions shall continue in full force and effect until written notice of modification or revocation is received and accepted by Bank (such notice to have no effect on any action previously taken by the Bank in reliance on these Resolutions). Bank may rely upon any form of notice, which it in good faith believes to be genuine or what it purports to be.

 

5)

The Resolutions are in full force and effect as of the date of this Certificate and are intended to replace, as of this date, any Resolutions previously given by the Company to Bank in connection with the matters described herein; these Resolutions and any borrowings or financial accommodations under these Resolutions have been properly noted in the corporate books and records, and have not been rescinded, revoked or modified; neither the foregoing Resolutions nor any actions to be taken pursuant to them are or will be in contravention of any provision of the articles of incorporation or bylaws of the Company or of any agreement, indenture or other instrument to which the Company is a party or by which it is bound; and to the extent the articles of incorporation or bylaws of the Company or any agreement, indenture or other instrument to which the Company is a party or by which it is bound require the vote or consent of shareholders of the Company to authorize any act, matter or thing described in the foregoing Resolutions, such vote or consent has been obtained.

 

In Witness Whereof, I have affixed my name as [Assistant] Secretary and have caused the corporate seal (where available) of said Company to be affixed on September 30, 2014.

 

 

 

 

 

[Assistant] Secretary*

 

 

 

 

 

 

*If the certifying officer is designated as the only signer in these resolutions then another corporate officer must also sign.  

 

 

 

 

 

 

 

 

 

Name:

 

 

 

Title: 

 

 

 

 
 

 

 

USA PATRIOT ACT
NOTICE
OF
CUSTOMER IDENTIFICATION

IMPORTANT INFORMATION ABOUT PROCEDURES FOR OPENING A NEW ACCOUNT

   

 

To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account.

 

WHAT THIS MEANS FOR YOU: when you open an account, we will ask your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver's license or other identifying documents.

 

 
 

 

 

SQUARE 1 BANK

 
 

AUTOMATIC DEBIT AUTHORIZATION

Member FDIC

 
   

 

To: Square 1 Bank

 

Re: Loan # ___________________________________

 

You are hereby authorized and instructed to charge account No. _________________________ in the name of VIVEVE, INC.

for facility fees, principal, interest and other payments due on above referenced loan as set forth below and credit the loan referenced above.

 
  ☒           Debit the Facility Fee as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
   
  ☒           Debit each interest payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
     
  ☒            Debit each principal payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
     
  ☒           Debit each payment for Bank Expenses as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
 

This Authorization is to remain in full force and effect until revoked in writing.

 

 

Borrower Signature /s/Scott Durbin

Date 

   
 

September 30, 2014

   
   
   

 

 
 

 

 

CLIENT MARKETING AUTHORIZATION

 

We are excited to have you as a Square 1 Bank client and want to spread the word about your success!

 

From press releases to mentions on social media sites, and all points in between, Square 1’s marketing and communications team is constantly seeking new opportunities to promote our clients and to connect them to prospects, existing customers, and the larger entrepreneurial/venture capital community.

 

If you complete the authorization below and return it to us, you are authorizing us to reference and/or include your company as part of our marketing and advertising efforts without further review or advance approval by you. Please select all areas that you approve.

 

All items listed below

List company as a Square 1 Bank customer on social media sites, including Twitter, LinkedIn, Facebook, Square 1 Bank corporate blog, or any other social media site

Press release including your company as a Square 1 Bank client (to include company name and description only ; may appear alongside other clients)

Press release including your company as a Square 1 Bank client ( general press release not focused on your company, but referring to your company as a client, and including your company’s name, description, and editorial comments; may appear alongside other clients)

Provide quote for inclusion in a Square 1 Bank press release

Use of company name and logo in Square 1 Bank marketing materials including corporate marketing collateral, website, social media sites, and other advertising campaigns

Provide quotes for inclusion in Square 1 Bank marketing materials including corporate marketing collateral, website, social media sites, and other advertising campaigns

Customer case study/application brief (success story to be posted on website, included in press kits and/or pitched to publications as potential articles)

Willing to participate in a video testimonial highlighting your banking relationship and experiences with Square 1 Bank

Other (please describe): ______________________________________________________

 

If you have questions, please contact your Square 1 banker, or our Marketing + Communications department at marketing@square1bank.com.

 

Please acknowledge your authorization by signing below:

 

Company Name:

VIVEVE, INC.

Authorized Signer:

/s/ Scott Durbin

Name:

Scott Durbin

Title:

CFO

Date:

September 30, 2014

 

 

 

Exhibit 10.2

 

INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of September 30, 2014 by and between Square 1 Bank (“ Bank ”) and VIVEVE, INC. , a Delaware corporation (“ Grantor ”).

 

RECITALS

 

A.      Bank has agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “ Loans ”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank and Grantor dated of even date herewith (as the same may be amended, modified or supplemented from time to time, the “ Loan Agreement ”; capitalized terms used herein are used as defined in the Loan Agreement).

 

B.      Bank is willing to extend and to continue to extend financial accommodations to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks and Patents to secure the obligations of Grantor under the Loan Agreement.

 

C.      Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement and all other agreements now existing or hereafter arising between Grantor and Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

 

AGREEMENT

 

To secure its obligations under the Loan Agreement and under any other agreement now existing or hereafter arising between Bank and Grantor, Grantor grants and pledges to Bank a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof (collectively, “ Intellectual Property Collateral ”).

 

This security interest is granted in conjunction with the security interest granted to Bank under the Loan Agreement. The rights and remedies of Bank with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Bank as a matter of law or equity. Each right, power and remedy of Bank provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Bank of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Bank, of any or all other rights, powers or remedies.

 

Grantor represents and warrants that Exhibits A, B, and C attached hereto set forth any and all intellectual property rights in connection to which Grantor has registered or filed an application with either the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

 

 
1. 

 

 

IN WITNESS WHEREOF , the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

 

Address of Grantor:

GRANTOR:

 
     
 

VIVEVE, INC.

 
150 Commercial Street    
Sunnyvale, CA 94086    

 

By:

/s/Scott Durbin

 
Attention: Title: CFO  
       
       
Address of Bank:

BANK:  

 
     
 

SQUARE 1 BANK  

 

406 Blackwell Street

   
Suite 240      

Durham, NC 27701

By: /s/Ben Colombo  

Attention: Benjermin Colombo

Title:

Sr. Vice President

 

 

 

 
2. 

 

 

EXHIBIT A

 

COPYRIGHTS

 

Description

 

Registration Number

 

Registration Date

         

None

       

 

 
 

 

 

EXHIBIT B

 

PATENTS

 

Description

 

Patent / Application

Number

 

Issue / Application

Date

         

Vaginal remodeling device and method

 

13/835,748

 

03/15/13

         

Vaginal remodeling device and methods

 

11/704,067

 

02/07/07

         

Vaginal remodeling device and methods

 

12/884,108

 

09/16/10

 

 

 

ALSO SEE ATTACHED PAGES.

 

 
 

 

 

  Page 1 of 22

September 22, 2014

Summary of Patent Applications being managed by ShayGlenn LLP

 

Our file

Title

Application No.

Filing Date

National phase date

Publication No.

Publication Date

Patent No.

Issue Date

Status

10095-701.101

VAGINAL REJUVENATION TREATMENT DEVICE AND METHODS

60/743,247

February 7, 2006

         

Closed

10095-701.201

VAGINAL REMODELING DEVICE AND METHODS

11/704,067

February 7, 2007

 

US-2007-0233191-A1

October 4, 2007

   

Published

10095-701.601

VAGINAL REMODELING DEVICE AND METHODS

PCT/US2007/003542

February 7, 2007

 

WO 2007/092610

August 16, 2007

   

Closed

10095-702.100

VAGINAL REMODELING DEVICE AND METHODS

61/243,686

September 18, 2009

         

Closed

10095-702.200

VAGINAL REMODELING DEVICE AND METHODS

12/884,108

September 16, 2010

 

US-2011-0178584-A1

July 21, 2011

   

Published

10095-702.600

VAGINAL REMODELING DEVICE AND METHODS

PCT/US2010/049045

September 16, 2010

 

WO 2011/034986

March 24, 2011

   

Closed

10095-702.AU0

VAGINAL REMODELING DEVICE AND METHODS

2010295586

September 16, 2010

March 20, 2012

       

Pending

10095-702.BR0

VAGINAL REMODELING DEVICE AND METHODS

BR 11 2012 006059 7

September 16, 2010

March 16, 2012

       

Pending

10095-702.CA0

VAGINAL REMODELING DEVICE AND METHODS

2,774,265

September 16, 2010

March 14, 2012

       

Pending

10095-702.CN0

VAGINAL REMODELING DEVICE AND METHODS

 

September 16, 2010

         

Unfiled

10095-702.EP0

VAGINAL REMODELING DEVICE AND METHODS

10817805.4

September 16, 2010

March 30, 2012

2477695

July 25, 2012

   

Published

10095-702.HK0

VAGINAL REMODELING DEVICE AND METHODS

10817805.4

September 16, 2010

August 22, 2012

2477695

July 25, 2012

   

Published

10095-702.IN0

VAGINAL REMODELING DEVICE AND METHODS

2321/DELNP/2012

September 16, 2010

March 16, 2012

       

Pending

10095-702.JP0

VAGINAL REMODELING DEVICE AND METHODS

2012-529890

September 16, 2010

March 16, 2012

2013-505069

February 14, 2013

   

Published

10095-702.KR0

VAGINAL REMODELING DEVICE AND METHODS

10-2012-7009840

September 16, 2010

April 17, 2012

10-2012-0100921

September 12, 2012

   

Published

10095-702.TW0

VAGINAL REMODELING DEVICE AND METHODS

099133093

September 29, 2010

 

201212879

April 1, 2012

   

Published

 

 
 

 

 

616 Dkt Summary

  Page 2 of 22

September 22, 2014

616     

DOCKET SUMMARY from Law Offices of Albert Wai-Kit Chan, PLLC

 

OUR

DOCKET

SUBJECT MATTER

DEADLINES / STATUS

1595

General Matters

September 9, 2011: Slides and other information sent by client.

September 12, 2011 : Conference call.

September 13, 2011: File histories sent by Jim Shay.

September 22, 2011 : Conference call. S. Lopez sent clarification of changes between generations 1 and 2 of invention.

September 29, 2011 : Conference call.

October 2, 2011: Conference call.

November 28, 2011: Conference call.

December 2, 2011: Portfolio Status sent.

December 13, 2011: Portfolio Status and filing strategy sent.

December 16, 2011: Conference call regarding overall filing strategy.

March 13, 2012: Meeting with client at Viveve.

December 20, 2012: Conference call regarding Hong Kong Short-term patent applications.

February 20, 2013 : Teleconference with P. Scheller on PCT, US and TW filings.

March 7 , 2013 : Teleconference with P. Scheller on assignments and filing strategy .

April 09 , 2013 : Teleconference with P. Scheller and S. Durbin on assignments and IP procurement.

December 19 , 2013 : Sent Patent Log per client’s request.

January 10, 2014 : Teleconference with P. Scheller .

April 2, 2014 : Sent Patent Log per client’s request.

July 10, 2014 : Teleconference with P. Scheller on national stage filings for 1614-A-PCT.

     
 

Docket Summary &

Action List

July 14, 2014: Last   Docket summary sent.

September 22, 2014 : Current Docket Summary.

     

1595-A

Co mpany name (in Chinese)

and related issues

March 15, 2012: Client decided on Chinese name ( 女康乐公司 ).

     

 

 
 

 

 

616 Dkt Summary

  Page 3 of 22

September 22, 2014

 

1595-B

Ownership/Assignment/

Agreement

March 29, 2012 : Draft assignments sent to client for execution.

April 19, 2012 : Followed up with client regarding execution of assignments.

April 23, 2012 : Client placed hold on docket.

January 22, 2013 : Client sent executed assignments (D. Galen to Viveve and Viveve employees to Viveve). 

March 04, 2013 : Client sent executed assignments (Stellartech to Viveve and Stellartech employeess to Stellartech). Assignment from Stellartech to Viveve did not contain the verbiage as proposed.

March 06, 2013 : Raised assignment issues for client to follow up.

March 07, 2013 : Client sent documents and agreements related to Dr. J. Parmer; Teleconference with client on assignments.

March 12, 2013 : Asked client to address two assignment issues.

March 13, 2013 : Client sent executed assignment (Stellartech to Viveve) containing the verbiage as proposed.

April 11, 2013 : Sent draft assignment (J. Parmer to Viveve) to client.

October 08 , 2013 : Client informed that it would be difficult to obtain assignment from Dr. Parmer.

March 31, 201 4 : Client asked for assistance in evaluating a merger agreement with regard to intellectual property.

     

1609

Intellectual Property Agreement with a Chinese partner

November 27, 2011: Received instructions from client to draft agreement re status of partner (Donna Bella) in China to defend IP.  

November 28, 2011: Draft sent to client.

December 1, 2011: Updated draft sent to client; Client needed nothing more.

J uly 08, 2013: Client requested to send the draft agreement; Sent draft to client.

J uly 12, 2013: Client indicated the previous draft agreement has not been sent to Donna Bella.

     

1625-TM-CN

Chinese Trademark Application for   女康 , Application No. 10892459 for International Class 10; Application No. 10892458 for International Class 41; Application No. 10892457 for International Class 44, All Filed May 10, 2012

STATUS: REGISTERED

 

August 14, 2013 :   Trademark registered.

Octob er 18 , 2013 : Sent Certificate to client.

August 13, 2023 :   Trademark expires.

 

DEADLINE :

February 13, 2023 - February 13, 2024: File renewal for   Trademark.

 

 
 

 

 

616 Dkt Summary

  Page 4 of 22

September 22, 2014

 

1601-0-(US)

VAGINAL REMODELING DEVICE AND METHODS, U.S. Serial No. 11/704,067, Filed February 07, 2 007, which claims benefit of U.S. Serial No. 6 0/743,247, Filed February 07, 2 006

STATUS: PENDING ( Prosecuted by client)

 

February 07, 2007 : Application filed.

October 04, 2007 : Application published as US20070233191A1 .

April 15, 2011 : Request for Continued Examination filed.

February 13, 2014 : Office Action issued.

June 09, 2014 : Response filed.

August 08, 2014 : Office Action issued .

[OA indicates there are allowable subject matters (method)]

 

DEADLINES:

November 08 , 2014 : File Response to Office Action

February 08, 2015 (abs) : File Response to Office Action

     

1601-(US)

VAGINAL REMODELING DEVICE AND METHODS, U.S. Serial No. 12/884,108 ,

Filed September 16, 2 010, which claims benefit of U.S. Serial No. 61/243,686, Filed September 18, 2009

Inventors:  

Jonathan B. PARMER , Ian F. SMITH , Chun-Chih CHENG , Patrick Karl HOWE , Sean Yasuo SULLIVAN , Jerome JACKSON , Stanley LEVY , Jr., Sherree Leigh LUCAS , Steven Marc LOPEZ

STATUS: PENDING ( Prosecuted by client)

 

September 16, 2010 : Application filed.

July 21 , 2011 : Application published as US20110178584A1 .

February 6, 2014 : final Office Action issued.

June 6, 2014 : Response filed.

June 26, 2014 : Advisory Action issued .

August 05, 2014 : Response and Request for Continued Examination filed.

August 27, 2014 : Office Action issued .

DEADLINES:

November 27 , 2014 : File Response to Office Action

February 27, 2015 (abs) : File Response to Office Action

     

1601-(PCT)

VAGINAL REMODELING DEVICE AND METHODS , International Application No. PCT/US2010/ 049045, Filed September 16, 2010, which claims benefit of U.S. Serial No. 61/243,686, Filed September 18, 2009

Inventors:  

Jonathan B. PARMER , Ian F. SMITH , Chun-Chih CHENG , Patrick Karl HOWE , Sean Yasuo SULLIVAN , Jerome JACKSON , Stanley LEVY , Jr., Sherree Leigh LUCAS , Steven Marc LOPEZ

STATUS: EXPIRED

 

September 16, 2010 : Application filed.

March 24, 2011 : Application published as WO2011/034986 .

     

 

 
 

 

 

616 Dkt Summary

  Page 5 of 22

September 22, 2014

 

1601- PCT- ( AU)

VAGINAL REMODELING DEVICE AND METHODS , Australian Application No. 2010295586, filed March 20, 2012, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

March 20, 2012 : National application filed.

April 12, 2012 : Application published as AU2010295586.

     

1601-PCT-(BR)

VAGINAL REMODELING DEVICE AND METHODS , Brazilian Application No. BR11 2012 006059 7, filed September 16, 2010, National Stage of International Application No. PCT/US2010/ 049045 

STATUS: PENDING ( Prosecuted by client)

     

1601-PCT-(CA)

VAGINAL REMODELING DEVICE AND METHODS , Canadian Application No. 2,774,265, filed March 14, 2012, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

March 14, 2012 : National application filed.

 

*Application published as CA2774265.

     

1601-PCT-CN

VAGINAL REMODELING DEVICE AND METHODS ( 修改阴道组织的仪器和方法 ) , Chinese Application No. 201080049557.4, Filed May 18, 2012, National stage of International Application No. PCT/US2010/049045

STATUS: PENDING

 

March 1 6 , 2012:  English application filed.

March 21, 2012: Reported filing of English application.

May 0 2, 2012: Chinese application filed.

May 18, 2012: Reported filing of Chinese application .

May 24, 2012: Copy of filed Request for Examination sent to client.

October 15, 2012: Notice of International Applications Entering the National Phase issued.

October 16, 2012: Notice reported to client.

March 1 3 , 201 3 :  Application published as CN102971047A .

March 20, 201 3 :  Notice of Publication and Entry into Substantive Examination issued .

October 08 , 2013 : Client informed that it would be difficult to obtain assignment from Dr. Parmer.

April 08, 2014 :  Request for updating applicant’s address filed and reported to client.

April 22, 2014 :  Notice of Granting Request for Changing Applicant's Address issued; reported to client.

 

Po tential assignment issue with J. Parmer

Waiting for Office Action

     

 

 
 

 

 

616 Dkt Summary

  Page 6 of 22

September 22, 2014

 

1601-PCT-(EP)

VAGINAL REMODELING DEVICE AND METHODS , European Application No. 2010817805, filed March 30, 2012, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

March 30, 2012 : National application filed.

July 25, 2012 : Application published as EP2477695 .

     

1601-PCT-EP-(HK)

VAGINAL REMODELING DEVICE AND METHODS , Hong Kong Standard Patent Application No. 12108243.4, Filed

August 22, 2012, corresponding to European Application No. 2010817805, filed March 30, 2012, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

August 22, 2012 : HK application filed.

December 07, 2012 : Application published as HK1167590 .

     

1601-PCT-(IN)

VAGINAL REMODELING DEVICE AND METHODS , Indian Application No. 2321/DELNP/2012, filed September 16, 2010, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

     

1601-PCT-(JP)

VAGINAL REMODELING DEVICE AND METHODS , Japanese Application No. 2012-529890, filed March 16, 2012, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

March 16, 2012 : National application filed.

February 14, 2013 : Application published as JP2013-505069 .

 

 
 

 

 

616 Dkt Summary

  Page 7 of 22

September 22, 2014

 

1601-PCT-(KR)

VAGINAL REMODELING DEVICE AND METHODS , Korean Application No. 10-2012-7009840, filed April 17, 2012, National Stage of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

April 17, 2012 : National application filed.

September 12, 2012 : Application published as KR10-2012-0100921.

     

1601-( TW )

VAGINAL REMODELING DEVICE AND METHODS, Taiwan Application No. 099133093, Filed September 29, 2 010, which claim priority of International Application No. PCT/US2010/ 049045

STATUS: PENDING ( Prosecuted by client)

 

September   29, 2 0 10 : Application filed.

April 01, 2012 : Application published as TW201212879 .

     

1602-CN-U

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ), Chinese Utility Model Application No. 201220099603.8, Filed March 16, 2012

Inventors:  

Jerome JACKSON ;

Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

December 27, 2012 : Notice of Grant issued.

April 10 , 201 3 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity .

     

1602-HK

VAGINAL REMODELING DEVICE ( 一种 修复女性 阴道组织的治疗器 ) , Hong Kong Short-term Patent App’l No. 13102976.9, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099603.8, filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued.

July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due .

     

 

 
 

 

 

616 Dkt Summary

  Page 8 of 22

September 22, 2014

 

1603-CN-U

VAGINAL REMODELING DEVICE WITH ELECTRODE FINGER HOLDER

( 一种具有电极手指套的修复女性阴道组织的治疗器 ) ,   Chinese Utility Model Application No. 201220099605.7, Filed March 16, 2012

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

January 08, 201 3 : Notice of Grant issued.

April 10 , 201 3 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

 

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity due .

     

1603-HK

VAGINAL REMODELING DEVICE WITH ELECTRODE FINGER HOLDER

( 一种具有电极手指套的修复女性阴道组织的治疗器 ) ,   Hong Kong Short-term Patent App’l No. 13102975.0, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099605.7, filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due .

     

1604-CN-U

VAGINAL REMODELING DEVICE WITH TEMPERATURE SENSOR ( 一种具有温度感应器的修复女性阴道组织的治疗器 ) ,   Chinese Utility Model Application No. 201220099618.4, Filed March 16, 2012

 

Inventors:   

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

 

October 17, 2012 : Notice of Grant issued.

December 28 , 2012 : Registration and Annuity Fees Paid.

February 13 , 2012 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity .

     

 

 
 

 

 

616 Dkt Summary

  Page 9 of 22

September 22, 2014

 

1604-HK

VAGINAL REMODELING DEVICE WITH TEMPERATURE SENSOR ( 一种具有温度感应器的修复女性阴道组织的治疗器 ) ,   Hong Kong Short-term Patent App’l No. 13102974.1, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099618.4, filed March 16, 2012 

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR

 

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

 

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due .

     

1607-CN-U

VAGINAL REMODELING DEVICE WITH DIRECTIONAL SENSORS ( 一种裝有方向感应器的修复阴道组织的治疗器 ) ,   Chinese Utility Model Application No. 201220099620.1, Filed March 16, 2012

 

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

 

October 31 , 2012 : Notice of Grant issued.

February 27, 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity .

     

1607-HK

VAGINAL REMODELING DEVICE WITH DIRECTIONAL SENSORS ( 一种裝有方向感应器的修复阴道组织的治疗器 ) ,   Hong Kong Short-term Patent App’l No. 13102973.2, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099620.1, filed March 16, 2012

Inventors:  

Jerome JACKSON ; Steven Marc LOPEZ ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due .

     

 

 
 

 

 

616 Dkt Summary

  Page 10 of 22

September 22, 2014

 

1608-CN-U

VAGINAL REMODELING DEVICE AND SYSTEM WITH DEPTH MARKERS   ( 一种具有深度标记的修改阴道组织的仪器和系统 ) ,   Chinese Utility Model Application No. 201220099634.3, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR  

STATUS: PATENTED

 

December 04 , 2012 : Notice of Grant issued.

March 20 , 2013 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity due .

     

1608-HK

 

VAGINAL REMODELING DEVICE AND SYSTEM WITH DEPTH MARKERS   ( 一种具有深度标记的修改阴道组织的仪器和系统 ) ,   Hong Kong Short-term Patent App’l No. 13102972.3, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099634.3, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due .

     

1611-CN

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ) ,   Chinese Application No. 201210069908.9, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

December 16, 2011:  Combining subject matters from 1602-CN and 1608-CN.

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client comments on figures.

March 15, 2012: Revised figures sent to client for approval.

March 20, 2012: Reported filing of application.

September 18, 2013 : Application published .

September 25, 2013 : Notice of Publication issued; Request for Examination filed.

October 08, 2013 : Notice of Entry into Substantive Examination issued.

October 29, 2013 : Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

October 31, 2013 : Client instructed not to file amendment.

March 12, 2014 : Client confirmed not to file HK standard application based on this application.

 

Waiting for Office Action

     

 

 
 

 

 

616 Dkt Summary

  Page 11 of 22

September 22, 2014

 

1612-CN

VAGINAL REMODELING DEVICE WITH TEMPERATURE SENSORS OR   DEPTH MARKERS ( 一种具有温度感应器或深度标记的修复阴道组织的治疗器 ) ,   Chinese Application No. 201210069910.6, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

 

STATUS: PENDING

 

December 16, 2011:  Combining subject matters from 1604-CN and 1608-CN .

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client approved.

March 20, 2012: Reported filing of application.

September 18, 2013 : Application published .

September 25, 2013 : Notice of Publication issued; Request for Examination filed.

September 30, 2013 : Notice of Entry into Substantive Examination issued.

October 29, 2013 : Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

November 04, 2013 : Voluntary Amendment on Specification and Claims filed.

November 0 5 , 2013 : Reported filed Voluntary Amendment to client.

March 12, 2014 : Client confirmed not to file HK standard application based on this application.  

September 04, 2014 : Office Action issued.

 

DEADLINES:

January 19 , 201 5 : File Response to Office Action

March 19, 2015 (abs) : File Response to Office Action

     

 

 
 

 

 

616 Dkt Summary

  Page 12 of 22

September 22, 2014

 

1613-CN

VAGINAL REMODELING DEVICE WITH DIRECTIONAL SENSORS OR DEPT H MARKERS   ( 一种具有方向感应器或深度标记的修复阴道组织的治疗器 ) ,   Chinese Application No. 201210069909.3, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

December 16, 2011:  Combining subject matters from 1607-CN and 1608-CN .

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client comments on figures.

March 15, 2012: Revised figures sent to client for approval.

March 20, 2012: Reported filing of application.

September 18, 2013 : Application published .

September 25, 2013 : Notice of Publication issued; Request for Examination filed.

October 09, 2013 : Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

November 04, 2013 : Voluntary Amendment on Specification and Claims filed.

November 0 5 , 2013 : Reported filed Voluntary Amendment to client.

March 12, 2014 : Client confirmed not to file HK standard application based on this application.

August 26, 2014 : Office Action issued.

September 03, 2014 : Reported Office Action to client.

 

DEADLINES:

January 10 , 201 5 : File Response to Office Action

March 10, 2015 (absolute) : File Response to Office Action

     

1614-CN

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ) ,   Chinese   Application No. 201210069906.X, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

December 16, 2011:  Combining subject matters from 1602-CN, 1603-CN, 1604-CN, 1607-CN and 1608-CN .

March 13, 2012: Draft application sent to client for approval.

March 14, 2012: Client comments on figures.

March 15, 2012: Revised figures sent to client for approval.

March 21, 2012: Reported filing of application.

September 18, 2013 : Application published .

September 25, 2013 : Notice of Publication issued; Request for Examination filed.

September 30, 2013 : Reported Notice of Publication and Notice of Entry into Substantive Examination to client.

October 31, 2013 : Client instructed not to file amendment.

March 12, 2014 : Client instructed to file HK standard application based on this application.

September 04, 2014 : Office Action issued.

 

DEADLINES:

January 10 , 201 5 : File Response to Office Action

March 10, 2015 (absolute) : File Response to Office Action

     

 

 
 

 

 

616 Dkt Summary

  Page 13 of 22

September 22, 2014

 

1614-CN-HK

VAGINAL REMODELING DEVICE ( 一种修复女性阴道组织的治疗器 ) ,   HK Application No. 14102600.2, filed March 15, 2014, corresponding to Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

March 12, 2014 : Client instructed to file HK standard application based on 1614-CN.

March 15, 2014 :   Request to Record a Designated Patent (Stage 1 application) filed.

March 17, 2014 : Reported to client on filed application.

April 25, 2014 : Accorded Filing Date Notification Letter issued and reported to client.

May 16, 2014 : Notification of Publication of the Request to Record issued

May 19, 2014 : Reported Notification of Publication of the Request to Record .

June 13, 2014 : Request to Record published.

June 17, 2014 : Reported publication of Request to Record .

 

File Request for Registration and Grant (Stage 2 application) once the Chinese application is granted

     

1614-CN-U

VAGINAL REMODELING DEVICE ( 一种修复女性阴道 组织的治疗器 ) , Chinese   Utility Model Application No. 201220099648.5, Filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENTED

December 24, 2012 : Notice of Grant issued.

April 10 , 201 3 : Patent Certificate issued.

March 13, 2014 : Reminded client on Annuity.

 

March 16, 2022 : Patent expires.

 

DEADLINE :

March 16, 2015 : Annuity due .

     

 

 
 

 

 

616 Dkt Summary

  Page 14 of 22

September 22, 2014

 

1614-HK

 

VAGINAL REMODELING DEVICE ( 一种修复女性阴道 组织的治疗器 ) , Hong Kong Short-term Patent App’l No. 13102971.4, filed March 11, 2013, which claims the priority of Chinese Utility Model App’l No. 201220099648.5, filed March 16, 2012

I nventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PATENETD

 

May 31, 2013: Notice of Publication of the Short-term Patent issued; Reported to client.

June 28, 2013 : Patent published; Certificate of Grant of Short Term Patent issued. July 3, 2013 : Reported issuance of Patent to client.

July 11, 2013 : Sent original Certificate and Publication to client.

 

March 11, 2021 : Patent expires.

 

DEADLINE :

March 11, 2017 : Renewal fee due .

     

 

 
 

 

 

616 Dkt Summary

  Page 15 of 22

September 22, 2014

 

1614-A-PCT

VAGINAL REMODELING DEVICE AND METHOD, International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

March 15, 2013: Application filed.

April 8, 2013: Client agreed to   postpone entry into Luxembourg until the EP case is allowed and to file application in UK, France, Germany and Italy.

April 11, 2013: Client sent prioritizations on countries for 1614 application: US, Europe, China, Hong Kong, Japan, Canada, Brazil, Mexico, Australia, India, South Korea, Singapore and Luxembourg .

April 12, 2013: Reported receipt of PCT Notifications of International Application Number and of the International Filing Date, Concerning Payment of Prescribed Fees, Receipt of Search Copy, and Invitation to Correct Defects in the International Application.

April 29, 2013: Priority document received by WIPO .

April 30, 2013 : Reported receipt of PCT Notification of Date of Receipt of Priority Document or of Priority Application Number; Client informed application is not entering China.

May 22, 2013 : Communication to Invitation to Correct Defects filed.

May 28, 2013 : Receipt of PCT Notices of Receipt of Record Copy and Priority Document.

June 06, 2013 : Receipt of PCT Notification of Transmittal of The International Search Report and The Written Opinion, International Search Report (ISR) and Written Opinion (WO).

June 15, 2013 : Client inquired about protection in Russia and considered to begin prosecution within the next few months.

August 02 , 2013 : Client confirmed not filing Amendment under Article 19.

September 19 , 2013 : Notification Concerning Availability of the Publication of the International Application issued; Application published.

October 14 , 2013 : Client sent updated list of prioritized countries and request quotation and informed will make final decision by June 16, 2014 .

October 17 , 2013 : PCT First Notice issued.

October 22 , 2013 : Reported issuance of PCT First Notice to client.

Novem ber 01 , 2013 : Sent options and cost for filing application in Saudi Arabia; Client would give further instructions.

June 16, 2014 : Reminded client on national stage entry.

July 10, 2014 : Informal Comments to Written Opinion filed with WIPO; Reported filed Informal Comments to client; Discussed with client on national entry.

July 11, 2014 : PCT Communication issued acknowledging receipt of Informal Comments.

July 14, 2014 : Reported PCT Communication to client .

July 22, 2014 : Client confirmed entering Europe, Japan, Canada, Brazil, Mexico, India, South Korea and Singapore.

July 23, 2014 : Client considered entering Russia, Australian or New Zealand after the 31-month deadline in view of financial status.

August 28, 2014 : Informed client that Canadian entry can be extended to September 16, 2015 with fee, but Mexican entry cannot be extended.

August 29, 2014 : Client instructed to postpone Canadian entry to September 16, 2015.

September 11, 2014 : Client confirmed not to file any Australian or New Zealand applications.

 

DEADLINES:

PCT National or Regional Phase Entry   

October 16, 2014: 31 months after earliest priority date

 

Countries/Regions Considered (as of 10/14/2013) :

Tier 1: US (1614-A-US), Europe, Japan, Canada, China/HK (1614-CN, 1614-CN-HK, 1614-CN-U, 1614-HK)

Tier 2: Brazil, Mexico, Australia, India, South Korea

Tier 3: Singapore, Taiwan (1614-A-TW), Russia, New Zealand, Saudi Arabia, UAE, Israel

Tier 4: All other markets

 

Per August 29, 2014 email , client may   file Canadian application by September 16, 2015.

     

 

 
 

 

 

616 Dkt Summary

  Page 16 of 22

September 22, 2014

 

1614-A-PCT-BR

VAGINAL REMODELING DEVICE AND METHOD , Brazilian Application No. 1120140228663, filed September 16, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

September 16, 2014: Application filed in Portuguese.

 

DEADLINE S :

November 15, 2014:  File Power of Attorney (original not required).

 

March 15, 2016: File Request for Examination and Voluntary Amendment.

 

June 15, 2015: Annuity Due.

     

1614-A-PCT-CA

VAGINAL REMODELING DEVICE AND METHOD , Canadian National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

August 29, 2014 : Client instructed to postpone Canadian entry to September 16, 2015.

 

DEADLINE S:

September 16, 2015 :  Absolute deadline to enter Canada (with late entry fee).

 

Need to r emind client by June 16, 2015   on filing application.

     

 

 
 

 

 

616 Dkt Summary

  Page 17 of 22

September 22, 2014
 

1614-A-PCT-EP

VAGINAL REMODELING DEVICE AND METHOD , European Application No. XXX, filed XXX, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

July 22, 2014 : Client confirmed filing European application.

 

DEADLINE S :

Octob er 16, 2014:  Absolute deadline to enter Europe.

     

1614-A-PCT-IN

VAGINAL REMODELING DEVICE AND METHOD , Indian Application No. XXX, filed XXX, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

July 22, 2014 : Client confirmed filing Indian application.

 

DEADLINE S :

Octob er 16, 2014:  Absolute deadline to enter India.

     

1614-A-PCT-JP

VAGINAL REMODELING DEVICE AND METHOD , Japanese Application No. Not yet known, filed September 16, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

September 16, 2014: Application filed in English; Petition for a 2-month extension for Japanese translation filed; Reported filed application to client.

 

DEADLINE S :

November 16, 2014:  File Japanese translation of application.  

March 15, 2016: File Request for Examination and Voluntary Amendment.

 

File Power of Attorney (original required).

     

 

 
 

 

 

616 Dkt Summary

  Page 18 of 22

September 22, 2014

 

1614-A-PCT-KR

VAGINAL REMODELING DEVICE AND METHOD , Korean Application No. XXX, filed XXX, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: TO BE FILED

 

July 22, 2014 : Client confirmed filing Korean application.

 

DEADLINE S :

Octob er 16, 2014:  Absolute deadline to enter Korea.

     

1614-A-PCT-MX

VAGINAL REMODELING DEVICE AND METHOD , Mexican Application No. MX/A/2014/011097, filed September 15, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

September 10, 2014: Client confirmed small entity status of Viveve.

September 15, 2014: Application filed in English.

 

 

DEADLINE S :

November 16, 2014:  File Spanish translation of application.  

 

Need to instruct FA by October 16, 2014 to translate application.

File Power of Attorney (original required).

     

 

 
 

 

 

616 Dkt Summary

  Page 19 of 22

September 22, 2014

 

1614-A-PCT-SG

VAGINAL REMODELING DEVICE AND METHOD , Singapore Application No. 11201405630T, filed September 11, 2014, National Stage of   International App’l No. PCT/US13/32066, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

September 11, 2014: Application filed.

September 19, 2014: Reported filed application to client.

 

DEADLINE S :

March 16, 2015 (36-month):  File Request for Examination .

March 16, 2015 (36-month):  File Request for Combined Search and Examination .

September 16, 2016 (54-month):  File Request for Supplementary Examination based on Prescribed Information. *

 

* File when there is any positive Search and Examination result, or a granted patent from any of the prescribed countries**. Must be filed before issuance of an Examination Report, if a Request for Examination or Request for Combined Search and Examination has been filed.

 

** Prescribed Countries are Australia, Canada, Europe, Japan, New Zealand, Republic of Korea, United Kingdom and United States of America.

     

1614-A-TW

VAGINAL REMODELING DEVICE AND METHOD, Taiwanese App’l No. 102109033, filed March 14, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

STATUS: PENDING

 

March 12, 2013: Client sent executed POA.

March 14, 2013: Application filed with English Specification and Figures.

March 18, 2013: Reported application filed.

March 27, 2013 : Sent revised Chinese Specification and Figures to Foreign Associate.

April 15, 2013 : Sent Priority document to Foreign Associate.

May 28, 2013 : Priority document and Chinese Specification and Figures filed.

May 30, 2013 : Reported filed Priority document, Chinese specification and Figure.

September 23, 2013 : Foreign Associate informed application will be published on October 01, 2013.

October 01 , 2013: Application laid-open .

October 14 , 2013: Request to correct inventor name filed.

October 15 , 2013: Client wanted to add “and/or exhaust” into the specification .

October 22 , 2013: Request to correct inventor name allowed.

October 28 , 2013: Reported   Correction of inventor name to client.

October  31 , 2013: Client would give instruction on filing Voluntary Amendment in early 2014.

 

DEADLINE:

March 14, 2016: Filing   Request for Substantive Examination and Voluntary Amendment .

     

 

 
 

 

 

616 Dkt Summary

  Page 20 of 22

September 22, 2014

 

1614-A-US

VAGINAL REMODELING DEVICE AND METHOD, U.S. Serial No. 13/835,748, filed March 15, 2013, claiming priority of Chinese Application No. 201210069906.X, filed March 16, 2012

 

Inventors:  

Donald I. GALEN ; Jerome JACKSON ; Steven Marc LOPEZ ; Russell MEIROSE ; Ian F. SMITH ; Srihari YAMANOOR

 

 

 

STATUS: PENDING

 

March 11, 2013: Sent client draft and formal papers to be filed

March 12, 2013: Client sent executed POA.

March 14, 2013: Client sent executed Declaration from five inventors.

March 15, 2013: Application and Preliminary amendment filed.

March 18, 2013: Reported application filed.

March 20 , 2013:   Client sent IDS checklist and relevant materials.

March 29 , 2013:   Client sent Declaration from Dr. Galen .

May 17 , 2013:   Reported filed Response to Notice to File Corrected Application Papers and Declaration from Dr. Galen.

May 22 , 2013:   Reported receipt of Filing Receipt and Notice of Acceptance of Power of Attorney;

May 29 , 2013:   Reported receipt of updated Filing Receipt .

July 1 7 , 2013 : IDS filed.

July 1 8 , 2013 : Reported filing of IDS.

September 19 , 2013 : Notice of Publication of Application issued; Application published as US 2013/0245728.

September 23 , 2013 : Reported published application to client.

September 19 , 201 4 : Sent IDS to client for review.

 

Waiting for action from USPTO

     

Other Ideas

SELF-ALIGNING TIP

October 07, 2011: Client sent idea in e-mail.

November 29, 2011: S. Lopez Update – “Viveve will not pursue this invention filing. Per previous discussion with K. Pope, idea incorporating ratcheting tip clocking mechanism deemed too expensive to manufacture against COGS target.” 

     
 

FLOATING HAND PIECE CABLE

October 07, 2011: Client sent idea in e-mail.

November 0 9, 2011: Not to be pursued.

     
 

VISUAL LOCATOR MARKING ON HAND PIECE

October 07, 2011: Client sent idea in e-mail.

November 29, 2011:  S. Lopez Update – “Visual markers incorporated into disposable treatment tip instead of hand piece. Embodiments for depth markers already submitted by Viveve under docket number 1608-CN.”

     

 

 
 

 

 

616 Dkt Summary

  Page 21 of 22

September 22, 2014

 

 

TREATMENT TIP SOFTWARE

October 04, 2011: Client sent idea in e-mail.

November 29, 2011 : S. Lopez Update – “Viveve will not pursue this invention filing in China. Per previous discussion with K. Pope, idea is likely considered a method and cannot be patented in China. Also, idea would provide too much confidential detail on how Viveve’s software operates the Viveve tip.” 

     
 

MANUFACTURING INSPECTION PROCESS TO CHECK TREATMENT TIP

October 04, 2011: Client sent idea in e-mail.

November 29, 2011 : S. Lopez Update – “Viveve will not pursue this invention filing in China. Per previous discussion with K. Pope, idea is a method and cannot be patented in China. Per K. Pope, may later elect to file method invention in the USA.” 

     
 

DIRECTIONAL SENSOR TO CONTROL CRYOGEN FLOW

September 20, 2011: Client sent idea in e-mail.

November 29, 2011:  S. Lopez Update – “Cryogen flow control using directional sensors already documented under summary submitted by Viveve for docket number 1607-CN.” 

     
 

MULTIPLE ELECTRODE CIRCUITS

September 20, 2011: Client sent idea in e-mail.

November 29, 2011:  S. Lopez Update – “Multiple electrode circuit embodiment already documented in distributed electrode design (conical, round, etc) under docket numbers 1602-CN and 1603-CN. Updated sketches for docket number 1603-CN due from Stellartech on 11-30-11.” 

     

 

Location: V-2

 

 
 

 

 

616 Dkt Summary

  Page 22 of 22

September 22, 2014

 

 

CONTACT INFORMATION:

 

Patricia Scheller

Chief Executive Officer and Director

Viveve, Inc 

150 Commercial Street,

Sunnyvale, CA 94086-5201

Telephone: 267-337-3583

Email: pscheller@viveve.com

 

 

Steve Lopez

Director, Operations

Viveve, Inc.

150 Commercial Street,

Sunnyvale, CA 94086-5201

Telephone: 650-321-3332 x 205

E-mail: slopez@viveve.com

 

 

Scott Durbin

Chief Financial Officer

Viveve, Inc.

150 Commercial Street,

Sunnyvale, CA 94086-5201

Email: sdurbin@viveve.com

 

   

X:\Central E-File of Cases\Dockets\Docket Summaries\VIVEVE\Docket Summary\2014 \616 Docket Summary 2014-09-22.doc

 

 
 

 

 

EXHIBIT C

 

TRADEMARKS

 

Description

 

Registration/ Application Number

 

Registration/ Application Date

         

VIVEVE

 

4,222,217

 

10/09/12

 

 

ALSO SEE ATTACHED PAGES.

 

 
 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

 

 
 

 

 

 

Exhibit 10.3

 

UNCONDITIONAL GUARANTY
(Viveve Medical, Inc.)

 

For and in consideration of the loan to VIVEVE, INC. (“ Borrower ”), which loan is made pursuant to a Loan and Security Agreement between Borrower and Square 1 Bank (“ Bank ”) of even date herewith, as amended from time to time (the “ Agreement ”), and acknowledging that Bank would not enter into the Agreement without the benefit of this Guaranty, the undersigned (“ Guarantor ”) hereby unconditionally and irrevocably guarantees the prompt and complete payment of all amounts that Borrower owes to Bank pursuant to the Agreement and performance by Borrower of the Agreement, as amended from time to time (collectively referred to as the “ Agreement ”), in strict accordance with its terms. All terms used without definition in this Guaranty shall have the meaning assigned to them in the Agreement.

 

1.      If Borrower does not pay any amount or otherwise perform its obligations in strict accordance with the Agreement, Guarantor shall immediately pay all amounts due thereunder (including, without limitation, all principal, interest, and fees) and otherwise to proceed to complete the same and satisfy all of Borrower’s obligations under the Agreement.

 

2.      The obligations hereunder are independent of the obligations of Borrower and any other person or entity, and a separate action or actions may be brought and prosecuted against Guarantor whether action is brought against Borrower or whether Borrower be joined in any such action or actions. Guarantor waives the benefit of any statute of limitations affecting its liability hereunder or the enforcement thereof, to the extent permitted by law. Guarantor’s liability under this Guaranty is not conditioned or contingent upon the genuineness, validity, regularity or enforceability of the Agreement.

 

3.      Guarantor authorizes Bank, without notice or demand and without affecting its liability hereunder, from time to time to (a) renew, extend, or otherwise change the terms of the Agreement or any part thereof, subject to and in accordance with Section 12.5 of the Agreement; (b) take and hold security for the payment of this Guaranty or the Agreement, and exchange, enforce, waive and release any such security, subject to and in accordance with the terms of the Agreement; and (c) apply such security and direct the order or manner of sale thereof as Bank in its sole discretion may determine, subject to and in accordance with the terms of the Agreement.

 

4.      Guarantor waives any right to require Bank to (a) proceed against Borrower, any other guarantor, or any other person; (b) proceed against or exhaust any security held from Borrower; or (c) pursue any other remedy in Bank’s power whatsoever. Bank may, at its election, exercise or decline or fail to exercise any right or remedy it may have against Borrower or any security held by Bank, including without limitation the right to foreclose upon any such security by judicial or nonjudicial sale, without affecting or impairing in any way the liability of Guarantor hereunder. Guarantor waives any defense arising by reason of any disability or other defense of Borrower, or by reason of the cessation from any cause whatsoever of the liability of Borrower. Guarantor waives any setoff, defense or counterclaim that Borrower may have against Bank. Guarantor waives any defense arising out of the absence, impairment or loss of any right of reimbursement or subrogation or any other rights against Borrower. Until all of the amounts that Borrower owes to Bank pursuant to the Agreement have been paid in full, Guarantor shall have no right of subrogation or reimbursement, contribution or other rights against Borrower, and Guarantor waives any right to enforce any remedy that Bank now has or may hereafter have against Borrower. Guarantor waives all rights to participate in any security in Borrower’s assets now or hereafter held by Bank. Guarantor waives all presentments, demands for performance, notices of nonperformance, protests, notices of protest, notices of dishonor, and notices of acceptance of this Guaranty and of the existence, creation, or incurring of new or additional indebtedness. Guarantor assumes the responsibility for being and keeping itself informed of the financial condition of Borrower and of all other circumstances bearing upon the risk of nonpayment of any indebtedness or nonperformance of any obligation of Borrower, warrants to Bank that it will keep so informed, and agrees that absent a request for particular information by Guarantor, Bank shall not have any duty to advise Guarantor of information known to Bank regarding such condition or any such circumstances.

 

 
1

 

 

5.      If Borrower becomes insolvent or is adjudicated bankrupt or files a petition for reorganization, arrangement, composition or similar relief under any present or future provision of the United States Bankruptcy Code, or if such a petition is filed against Borrower, and in any such proceeding some or all of any indebtedness or obligations under the Agreement are terminated or rejected or any obligation of Borrower is modified or abrogated, or if Borrower’s obligations are otherwise avoided for any reason, Guarantor agrees that Guarantor’s liability hereunder shall not thereby be affected or modified and such liability shall continue in full force and effect as if no such action or proceeding had occurred. This Guaranty shall continue to be effective or be reinstated, as the case may be, if any payment must be returned by Bank upon the insolvency, bankruptcy or reorganization of Borrower, Guarantor, any other guarantor, or otherwise, as though such payment had not been made.

 

6.      Any indebtedness of Borrower now or hereafter held by Guarantor is hereby subordinated to any indebtedness of Borrower to Bank; and during the existence of an Event of Default such indebtedness of Borrower to Guarantor shall be collected, enforced and received by Guarantor as trustee for Bank and be paid over to Bank on account of the indebtedness of Borrower to Bank.

 

7.      Guarantor agrees to pay reasonable attorneys’ fees and all other costs and expenses which may be incurred by Bank in the enforcement of this Guaranty. No terms or provisions of this Guaranty may be changed, waived, revoked or amended without Bank’s prior written consent. Should any provision of this Guaranty be determined by a court of competent jurisdiction to be unenforceable, all of the other provisions shall remain effective. This Guaranty, together with any agreement (including without limitation any security agreement or any pledge agreement) executed in connection with this Guaranty, embodies the entire agreement among the parties hereto with respect to the matters set forth herein, and supersedes all prior agreements among the parties with respect to the matters set forth herein. No course of prior dealing among the parties, no usage of trade, and no parol or extrinsic evidence of any nature shall be used to supplement, modify or vary any of the terms hereof. There are no conditions to the full effectiveness of this Guaranty. Bank may assign this Guaranty without in any way affecting Guarantor’s liability under it. This Guaranty shall inure to the benefit of Bank and its successors and assigns. This Guaranty is in addition to the guaranties of any other guarantors and any and all other guaranties of Borrower’s indebtedness or liabilities to Bank.

 

 
2

 

 

8.      Guarantor represents and warrants to Bank that (i) Guarantor has taken all necessary and appropriate action to authorize the execution, delivery and performance of this Guaranty and (ii) execution, delivery and performance of this Guaranty do not conflict with or result in a breach of or constitute a default under Guarantor’s organizational documents or any agreement to which it is party or by which it is bound.

 

9.      Guarantor shall do all of the following:

 

9.1      Guarantor shall maintain its existence, remain in good standing in its jurisdiction of organization, provided that nothing herein shall prevent
Guarantor from changing its jurisdiction of organization to the State of Delaware or the State of Nevada in any manner permitted by applicable law, and continue to qualify in each jurisdiction in which the failure to so qualify could have a material adverse effect on the condition, prospects, operations or business of Guarantor. Guarantor shall maintain in force all licenses, approvals and agreements, the loss of which could have a material adverse effect on its financial condition, operations or business.

 

9.2      Guarantor shall comply with the provisions of its organizational documents, and shall not amend any such documents in any manner materially adversely affecting Bank without Bank’s prior written consent, which will not be unreasonably withheld. Guarantor shall comply with all statutes, laws, ordinances, directives, orders, and government rules and regulations to which it is subject if non-compliance with such laws could materially adversely affect the financial condition, operations or business of Guarantor.

 

10.      This Guaranty shall be governed by, and construed in accordance with, the internal laws of the State of California, without regard to principles of conflicts of law. Jurisdiction shall lie in the State of California. All disputes, controversies, claims, actions and similar proceedings arising hereunder shall be brought in the Superior Court of San Mateo County, California or the United States District Court for the Northern District of California, except as provided below with respect to arbitration of such matters. BANK AND GUARANTOR EACH ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED. EACH OF THEM, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT, WITH COUNSEL OF THEIR CHOICE, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT ANY OF THEM MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS GUARANTY OR ANY RELATED INSTRUMENT OR LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS GUARANTY OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTION OF ANY OF THEM. THESE PROVISIONS SHALL NOT BE DEEMED TO HAVE BEEN MODIFIED IN ANY RESPECT OR RELINQUISHED BY BANK OR GUARANTOR, EXCEPT BY A WRITTEN INSTRUMENT EXECUTED BY EACH OF THEM. If the jury waiver set forth in this Section 10 is not enforceable, then any dispute, controversy, claim, action or similar proceeding arising out of or relating to this Guaranty shall be settled by final and binding arbitration held in San Mateo County, California in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with those rules. The arbitrator shall apply California law to the resolution of any dispute, without reference to rules of conflicts of law or rules of statutory arbitration. Judgment upon any award resulting from arbitration may be entered into and enforced by any state or federal court having jurisdiction thereof. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this Section. The costs and expenses of the arbitration, including without limitation, the arbitrator’s fees and expert witness fees, and reasonable attorneys’ fees, incurred by the parties to the arbitration may be awarded to the prevailing party, in the discretion of the arbitrator, or may be apportioned between the parties in any manner deemed appropriate by the arbitrator. Unless and until the arbitrator decides that one party is to pay for all (or a share) of such costs and expenses, both parties shall share equally in the payment of the arbitrator’s fees as and when billed by the arbitrator.

 

 
3

 

 

11.      To secure all amounts owing under this Guaranty, Guarantor grants Bank a security interest in all of Guarantor’s interest in any capital stock or equity interest in Borrower, now owned or hereafter arising, and all proceeds thereof (the “Pledged Collateral”). The term “Pledged Collateral” shall also include any securities, instruments or distributions of any kind issuable, issued or received by Guarantor upon conversion of, in respect of, or in exchange for any other Pledged Collateral, including, but not limited to, those arising from a stock dividend, stock split, reclassification, reorganization, merger, consolidation, sale of assets or other exchange of securities or any dividends or other distributions of any kind upon or with respect to the Pledged Collateral.

 

12.      All payments made by Guarantor hereunder will be made free and clear of, and without deduction or withholding for, any present or future taxes, levies, imposts, duties, fees, assessments or other charges of whatever nature now or hereafter imposed by any governmental authority or by any political subdivision or taxing authority thereof or therein with respect to such payments (but excluding any tax imposed on or measured by the net income or profits of a Bank pursuant to the laws of the jurisdiction in which it is organized or the jurisdiction in which the principal office or applicable lending office of such Bank is located or any subdivision thereof or therein) and all interest, penalties or similar liabilities with respect thereto (all such non-excluded taxes, levies, imposts, duties, fees, assessments or other charges being referred to collectively as “Taxes”). If any Taxes are so levied or imposed, Guarantor agrees to pay the full amount of such Taxes, and such additional amounts as may be necessary so that every payment of all amounts due under this Guaranty, after withholding or deduction for or on account of any Taxes, will not be less than the amount provided for herein and in the Loan Documents.

 

IN WITNESS WHEREOF , the undersigned Guarantor has executed this Guaranty as of September 30, 2014.

 

 

VIVEVE MEDICAL, INC.

 
     
 

By:

/s/ Scott Durbin  
       
  Title: CFO  

 

 

4

Exhibit 10.4

 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW.

 

WARRANT TO PURCHASE STOCK

 

Corporation:

VIVEVE MEDICAL, INC.

Number of Shares:

471,698

Class of Stock:

Common Stock

Initial Exercise Price:

$0.53 per share

Issue Date:

September 30, 2014

Expiration Date:

September 30, 2024

 

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, the receipt of which is hereby acknowledged, Square 1 Bank or its assignee (“ Holder ”) is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the “ Shares ”) of the corporation (the “ Company ”) at the initial exercise price per Share (the “ Warrant Price ”) all as set forth above and as adjusted pursuant to Article 2 of this warrant, subject to the provisions and upon the terms and conditions set forth in this warrant.

 

ARTICLE 1

EXERCISE

 

1.1      Method of Exercise. Holder may exercise this warrant by delivering this warrant and a duly executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.

 

1.2      Conversion Right. In lieu of exercising this warrant as specified in Section 1.1, Holder may from time to time convert this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this warrant minus the aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Section 1.3.

 

1.3      Fair Market Value. If the Shares are quoted on any over the counter market maintained by OTC Markets Group, Inc. or listed on any national stock exchange in the United States, the fair market value of the Shares shall be the closing price of the Shares (or the closing price of the Company’s stock into which the Shares are convertible) reported for the business day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment.

 

 
1.

 

 

1.4      Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this warrant has not been fully exercised or converted and has not expired, a new warrant representing the Shares not so acquired.

 

1.5      Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, on surrender and cancellation of this warrant, the Company at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like tenor.

 

1.6      Repurchase on Sale, Merger, or Consolidation of the Company.

 

1.6.1      Acquisition . ” For the purpose of this warrant, “Acquisition” means (a) any sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger or sale of the voting securities of the Company or any other transaction where the holders of the Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction.

 

1.6.2      Assumption of Warrant. In the case of a reincorporation of the Company, this warrant shall be assumed by the successor entity. If upon the closing of any other Acquisition, the successor entity assumes the obligations of this warrant, then this warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised portion of this warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly. The Company shall use reasonable efforts to cause the surviving corporation to assume the obligations of this warrant.

 

1.6.3      Nonassumption. If upon the closing of any Acquisition the successor entity does not assume the obligations of this warrant and Holder has not otherwise exercised this warrant in full, then this warrant shall automatically convert pursuant to Section 1.2 and thereafter Holder shall participate in the Acquisition on the same terms as other holders of the same class of securities of the Company.

 

ARTICLE 2

ADJUSTMENTS TO THE SHARES

 

2.1      Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable in common stock, or other securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred.

 

 
2.

 

 

2.2      Reclassification, Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this warrant, Holder shall be entitled to receive, upon exercise or conversion of this warrant, the number and kind of securities and property that Holder would have received for the Shares if this warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Articles of Incorporation upon the closing of a registered public offering of the Company’s common stock. The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events.

 

2.3      Adjustments for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are split or multiplied, by reclassification or otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased.

 

2.4      Intentionally Omitted.

 

2.5      No Impairment. The Company shall not, by amendment of its charter documents or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment.

 

2.6      Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.

 

2.7      Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of the Warrant and the Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder an amount computed by multiplying the fractional interest by the fair market value of a full Share.

 

 
3.

 

 

ARTICLE 3

REPRESENTATIONS AND COVENANTS OF THE COMPANY

 

3.1      Representations and Warranties. The Company hereby represents and warrants to the Holder as follows:

 

(a)      The initial Warrant Price referenced on the first page of this warrant is not greater than the fair market value of the Shares as of the date of this warrant.

 

(b)      All Shares which may be issued upon the exercise of the purchase right represented by this warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

 

(c)      The Company’s capitalization table attached to this warrant is true and complete as of the Issue Date.

 

3.2      Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution upon its common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) to effect any reclassification or recapitalization of common stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (1) at least 20 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of common stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and (2) in the case of the matters referred to in (c) and (d) above at least 20 days prior written notice of the date when the same will take place (and specifying the date on which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event).

 

3.3      Information Rights. So long as the Holder holds this warrant and/or any of the Shares, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communiques to the shareholders of the Company, (b) within ninety (90) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements; provided, however, that so long as the Company is subject to the reporting obligations of Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and files all such required reports on a timely basis (including pursuant to Rule 12b-25 promulgated under the Exchange Act), the Company shall be required only to notify the Holder that the filing has been made to satisfy the requirements of subsections (b) and (c) herein.

 

 
4.

 

 

3.4      Intentionally Omitted.

 

ARTICLE 4

MISCELLANEOUS

 

4.1      Term: Exercise Upon Expiration. This warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above. If this warrant has not been exercised prior to the Expiration Date, this warrant shall be deemed to have been automatically exercised on the Expiration Date by “cashless” conversion pursuant to Section 1.2.

 

4.2      Legends. This warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form:

 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW.

 

4.3      Compliance with Securities Laws on Transfer. This warrant and the Shares issuable upon exercise of this warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee and an opinion of legal counsel reasonably acceptable to the Company.

 

4.4      Transfer Procedure. Subject to the provisions of Section 4.3, Holder may transfer all or part of this warrant or the Shares issuable upon exercise of this warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of the warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable).

 

4.5      Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. All notices to the Holder shall be addressed as follows:

 

Square 1 Bank

Attn: Warrant Administrator

406 Blackwell Street, Suite 240

Durham, NC 27701                              

 

4.6      Amendments. This warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.

 

 
5.

 

 

4.7      Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

 

4.8      Governing Law. This warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law.

 

 

 

VIVEVE MEDICAL, INC.

 
     
 

By:

/s/Scott Durbin

 
       
 

Name:

Scott Durbin

 
       
 

Title:

CFO

 

 

 
6.

 

 

APPENDIX 1

 

NOTICE OF EXERCISE

 

1.      The undersigned hereby elects to purchase ______________ shares of the ______________ stock of VIVEVE MEDICAL, INC. pursuant to the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full.

 

2.      The undersigned hereby elects to convert the attached warrant into shares in the manner specified in the warrant. This conversion is exercised with respect to ______________ of the shares covered by the warrant.

 

[Strike paragraph that does not apply.]

 

3.      Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:

 

Square 1 Bank

Attn: Warrant Administrator

406 Blackwell Street, Suite 240

Durham, NC 27701

 

4.      The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.

 

SQUARE 1 BANK or Registered Assignee

 

 


(Signature)

 

 


(Date)